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1. INTRODUCTION
Post-translational modiﬁcations (PTMs) of histone proteins are
a hallmark of epigenetic regulation. They provide a mechanism
to modulate chromatin structure and constitute the main
features of the so-called “histone code”.1 The proposed
function of this code is to integrate exogenous and endogenous
signals into a diverse set of histone PTM patterns to enable the
epigenetic control of gene expression. The key regulators of this
process are the so-called “writers” and “erasers”, which act by
dynamically modifying histones, and other chromatin-associ-
ated proteins, as well as the “readers”, which interpret these
PTMs, thereby facilitating the downstream activation or
repression of gene expression.2
The writers are histone-modifying enzymes that can be
grouped according to their amino acid substrate preference,
aﬀecting mainly lysine, arginine, and serine residues.3 These
enzymes can be further classiﬁed according to the type of
covalent modiﬁcation that they catalyze. Histone modiﬁcations
include acetylation, methylation, phosphorylation, and the
more recently described modiﬁcations of citrullination,
ubiquitination, SUMOylation, proline isomerization, O-GlcNA-
cylation, and ADP-ribosylation.1b,3 On the basis of detailed
mass spectrometric analyses, there are at least 15 diﬀerent types
of covalent histone modiﬁcations,4 and since histone proteins
are modiﬁed at multiple sites, and diﬀerent stoichiometries, the
total number of histone marks is >160.5 Although our
understanding of how histone modiﬁcations contribute to the
epigenetic control of gene transcription has grown immensely
over the past ∼15 years, the precise impact of this vast number
of modiﬁcations, not to mention the crosstalk between them,
has yet to be fully realized.
Histone proteins are small, highly basic proteins consisting of
a globular domain and ﬂexible N-terminal and C-terminal tails
that protrude from the nucleosome. The core histone proteins
(histones H2A, H2B, H3, and H4) form an octameric particle
consisting of two H2A−H2B dimers and an H3−H4 tetramer,
around which wrap two helical turns of DNA (∼150 bp).6 This
structure, which is generally termed a nucleosome, comprises
the basic building block of higher order chromatin structures
that are further organized through the function of linker
histones such as histone H1. On the basis of nucleosome
positioning studies, around 80% of the yeast genome and even
99% of the mappable genome of human granulocytes is
occupied by nucleosomes, thereby highlighting the importance
of nucleosome-packaged DNA for eukaryotic cells.7 Impor-
tantly, while histone PTMs are found throughout the entire
protein, they are most often clustered within the N-terminal
tail. Although research on histone lysine modiﬁcations has
drawn considerable attention and even resulted in the approval
of novel anticancer drugs,8 the modiﬁcation of histone arginine
residues is a recently emerging nucleosomal mark of similar
importance (Figure 1).
Arginine residues possess a characteristic guanidinium-
containing side chain that has one of the highest pKa values
(pKa = 12.5; this value refers to the side chain of the free amino
acid in aqueous solution at 25 °C) of all amino acids;9 thus,
these residues are protonated and positively charged at
physiological pH. The high pKa value also renders the
guanidinium group a poor nucleophile and as such presents a
considerable challenge for modifying this residue. In addition to
its positive charge, the arginine guanidinium contains ﬁve
potential hydrogen bond donors that can be used to interact
with other polar groups (Figure 2). Notably, the strong charge
favors the location of arginine residues to the outer hydrophilic
surfaces of proteins. Consequently, they are readily accessible
for binding to molecules with negative charges, e.g., nucleic
acids. In this respect, arginines are one of the most common
residues involved in the formation of protein/DNA and
protein/RNA complexes.10 The frequent use of arginine for
this type of interaction can be explained by opposite charge
attraction, the length and ﬂexibility of the side chain, and the
ability to produce excellent hydrogen-bonding geometries with
nucleobases or phosphate groups (Figure 2). For example, the
orientation of the planar guanidinium nitrogen atoms perfectly
matches with the oxygen atoms of phosphate (present in
nucleic acids and phosphoproteins) to form a stable bidentate
salt bridge that is at least 2-fold stronger than the interaction
between a lysine ammonium group and a phosphoryl group.11
In addition, the possible bidentate hydrogen-bonding ability of
arginine not only confers a more economical way to optimize
bond energies but also increases speciﬁcity in the recognition of
speciﬁc DNA sequences, as exempliﬁed by the recognition of
guanine (Figure 2).10a
Given the ability to form these types of interactions, it is clear
that the post-translational modiﬁcation of an arginine residue
could have dramatic eﬀects on cell signaling and, like other
Figure 1. N-terminal tails of histone proteins are the preferred targets
of histone-modifying enzymes. The major modiﬁcations of histone
arginine residues are citrullination and methylation. Abbreviations: Cit,
citrulline; MMA, monomethylarginine; ADMA, asymmetric dimethy-
larginine; SDMA, symmetric dimethylarginine.
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histone modiﬁcations, contribute to disease pathogenesis. In
fact, there is increasing experimental evidence to suggest that
the dysregulation of arginine-modifying enzymes plays pivotal
roles in cancer, inﬂammatory diseases, neurodegenerative
diseases, and other conditions.8b,12 In this review, we aim to
summarize the current knowledge surrounding the post-
translational modiﬁcation of histone arginine residues, focusing
on enzyme classes that catalyze the citrullination and
methylation of arginine residues as well as noncanonical
arginine modiﬁcations such as phosphorylation, ADP-ribosyla-
tion, and arginylation. The major focus will be given to the
PADs (protein arginine deiminases) and PRMTs (protein
arginine methyltransferases).
2. HISTONE CITRULLINATION (ARGININE
DEIMINATION)
2.1. Overview of Protein Citrullination
Protein citrullination is an emerging PTM that results from the
conversion of peptidyl arginine to peptidyl citrulline. This PTM
is catalyzed by the calcium-regulated PAD family of enzymes
(Figure 3).13 Due to the exchange of an imine for a carbonyl
group, this reaction is referred to as deimination. The PAD-
catalyzed hydrolysis of a guanidinium group has a profound
eﬀect on the electrostatics and the hydrogen-bonding potential
of the original side chain as citrulline is neutral and contains
two hydrogen bond acceptor sites and only three potential
hydrogen bond donors compared to the ﬁve present in arginine
(Figure 4). Despite the large electronic eﬀects, the overall
change in mass is marginal: −0.02 Da, accounting for the extra
proton in the charged guanidinium group, or +0.98 Da, as
encountered during mass spectrometric analyses of the neutral
guanidine form.
There are ﬁve human PAD isozymes, including PAD1,
PAD2, PAD3, and PAD4, which are catalytically active, and
PAD6, for which no activity has been detected.13,14 On the
basis of the historic nomenclature, human PAD5 was thought
to represent a novel PAD family member that diﬀered from
mouse PAD4.15 However, detailed sequence and expression
analysis revealed that human PAD5 was the mouse PAD4
orthologue. As such, it was renamed PAD4, leaving PAD5
unused.13 The PADs share a high degree of sequence
conservation (70−95% identity among each isozyme in
diﬀerent mammals and 50−55% identity between individual
isozymes within one species) (Figure 5) and possess low pI
values, typically around 5.8.13 The net negative charge is
thought to be instrumental for recognizing the positive charge
of a substrate arginine residue as well as for the binding of
essential calcium ions (see below).
The PADs are widely distributed in higher eukaryotes, and
their expression as well as activity is associated with the
regulation of gene expression and various developmental stages
(see below).13 PAD1 is highly expressed in the epidermis and
uterus, PAD2 is expressed in numerous tissues, PAD3 is mainly
found in the skin and hair follicles, PAD4 is primarily expressed
in granulocytes, macrophages, and neutrophils, and PAD6 is
expressed in oocytes and embryos.15,16 Within the cell, PAD
protein and/or activity are detected in various cellular
compartments, including the cytoplasm, mitochondria, and
nucleus.17 Although PAD4, which contains a canonical nuclear
localization signal (NLS; P56PAKKKST63) was long thought to
be the only nuclear PAD enzyme,17a emerging evidence
indicates that other PAD isozymes can localize to the nucleus
as well.17b For example, PAD2 was recently found in the
nucleus of murine mammary epithelial cells, and in nuclear
fractions of astrocytes as well as hippocampal neurons of
scrapie-infected mice.17b,c
2.2. Structure and Mechanism of the PADs
PADs (EC 3.5.3.15) belong to the guanidino-group-modifying
branch of the pentein superfamily.18 They are calcium-regulated
cysteine hydrolases that act on carbon−nitrogen bonds. Other
members of this family include the amidinotransferases (ATs),
which catalyze the transamidination reaction of nonpeptidyl
arginine to glycine, thereby generating the creatine precursor
Figure 2. Bidendate interactions of the arginine guanidinium group exempliﬁed by (i) the carboxyl group of aspartate (trypsin−peptide complex,
PDB code 1OX1) (left), (ii) the phosphoryl group of phosphotyrosine (SH2−pTyr, PDB code 4F5B) (middle),227 and (iii) atoms O6 and N7 of
guanine (p53−DNA, PDB code 3TS8) (right).228
Figure 3. PAD enzymes catalyze the hydrolytic conversion of peptidyl
arginine residues into citrulline.
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guanidinoacetate, the arginine deiminases (ADIs), which act on
nonpeptidyl arginine and the dimethylarginine dimethylamino-
hydrolase (DDAH) enzymes, which are highly selective for
methylated nonpeptidyl arginine.18a In contrast to these
enzyme groups, the PADs only act on peptidyl arginine
residues and require at least an N-terminal amide bond and a
C-terminal carbonyl for eﬃcient substrate recognition.19 The
PADs are highly eﬃcient enzymes as exempliﬁed by PAD1,
which exhibits a rate enhancement over the noncatalyzed
reaction (kcat/knon) under near-neutral pH conditions of ∼8.5 ×
1011 (kcat = 0.45 s
−1 versus knon = 5.3 × 10
−13 s−1). In terms of
catalytic proﬁciency (i.e., (kcat/KM)/knon), evaluated by
comparing the second-order rate constant (kcat/KM = 4.1 ×
103 M−1 s−1) with the rate of the spontaneous reaction in
neutral solution in the absence of a catalyst (knon = 5.3 × 10
−13
s−1), the rate enhancement is 8 × 1015 M−1 (Table 1).20
2.2.1. PAD Structure. As with other members of the
guanidino-group-modifying pentein family, PADs contain a
catalytic α/β propeller domain that is located on its C-terminal
half.18b,21 PADs typically exist as homodimeric proteins in
solution and, according to crystallographic studies, bind in a
head-to-tail fashion (Figure 6A).21 The dissociation constant
(Kd) for PAD4 dimer formation was estimated to be ∼450
nM.22 Moreover, dimerization was shown to be important for
activity and cooperativity, since disruption of the dimer
interface reduces the activity by 50−75%.22 The dimerization
interface covers a large surface area of ∼2000 Å2 comprising
multiple contacts between the N-terminal domain of one
protomer and the catalytic domain of the other protomer. Each
subunit comprises two domains, including the N-terminal
domain, which can be further subdivided into two immuno-
globulin-like (Ig) subdomains that are proposed to be
important for protein−protein interactions and to facilitate
substrate selection.21 The C-terminal catalytic domain harbors
all the active site residues, and the dimeric PAD4 structure
revealed that both active site cavities are located on the same
dimer face and are separated by ∼65 Å (Figure 6B).
2.2.2. Calcium Dependency of PAD Enzymes. The
crystal structure of PAD4 further showed that each protomer
contains two bound calcium ions (Ca1, Ca2) in the catalytic
domain and three additional calcium ions (Ca3, Ca4, and Ca5)
located in the Ig II subdomain (Figure 7). Although calcium
binding is crucial for catalytic activity, it has no inﬂuence on
dimer formation.21,22 Detailed comparisons of calcium-free and
calcium-bound PAD4 and PAD2 indicate that calcium binding
has a profound eﬀect on the PAD structure, and is critical for
forming a catalytically competent active site (Figure 8).21,23
Notably, loop regions comprising the active site cavity are
largely disordered in the absence of calcium and only become
visible (ordered) in the presence of calcium. Calcium ions Ca3,
Ca4, and Ca5 bind to a conserved negatively charged region
and are thought to stabilize the structure, whereas Ca2 and in
particular Ca1 are positioned close to the bottom of the active
site cleft and are thus essential for maintaining the architecture
of the active site (Figure 8).21 This calcium-induced conforma-
tional change is also highlighted by the fact that C645 in PAD4
and C647 in PAD2, the nucleophilic cysteine residue, moves
≥5 Å into the active site when calcium binds to the enzyme.
The organization of the active site cavity of calcium-bound,
substrate-free PAD4 is almost identical to that of the substrate-
bound complex, indicating that substrate binding has little
eﬀect on the formation of the active site.21 On the basis of
calcium titration experiments with PAD2, which were
monitored by X-ray crystallography, Ca1 and Ca6 bind ﬁrst,
and Ca3, Ca4, and Ca5 bind next and cause a conformational
change that generates the Ca2 site. Calcium binding at Ca2 is
critical for triggering the movement of the active site cysteine
into a catalytically competent position. Despite Ca2 binding
last, these titration experiments, coupled with mutagenesis and
hydrogen/deuterium exchange experiments, indicate that Ca3,
Ca4, and Ca5 act as a calcium switch to control the overall
calcium dependence of the enzyme.
Notably, the metal dependency of PAD4 was tested using
various cations, including barium, calcium, magnesium,
manganese, samarium, strontium, and zinc.19 None of the
examined metals except calcium could eﬃciently activate the
catalytic activity of PAD4. Conversely, some of these metals
were even decent PAD inhibitors. The most potent inhibition
was accomplished using samarium (present as Sm3+ ion in
samarium sulfate, Sm2(SO4)3) and zinc (present as Zn
2+ ion in
zinc chloride, ZnCl2), which possessed IC50 values of 40 and
750 μM, respectively. Thus, calcium binding is a critical
prerequisite for proper substrate binding.
The strict calcium dependency of PAD activity is further
reﬂected by the fact that calcium activates the enzyme by more
than 10000-fold. Also notable is the fact that full PAD4 activity
requires a high concentration of calcium and the half-saturation
constant for calcium binding (K0.5,Ca) ranges from 130 to 710
μM depending on the substrate.19,22 How the PADs are
activated in cells is, however, still unknown. For instance, the
concentration of calcium required for maximal PAD4 activity is
100−1000-fold higher than that observed in activated cells.
Therefore, it is currently unclear how PADs are eﬃciently
activated in vivo and/or how the calcium dependency is
Figure 4. Electrostatic surface potential and hydrogen bond donor/acceptor sites of the side chains of arginine and citrulline. Hydrogen bond donor
sites are highlighted in red, whereas hydrogen bond acceptor sites are depicted in blue. Cα denotes the α-carbon. Charge potentials were rendered by
using SPARTAN (Wavefunction Inc.), with negative electrostatic charges shown in red, positive charges in blue, and neutral charges in green.
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lowered inside cells. It has been proposed that PADs may
temporarily locate to intracellular calcium channels that can
provide local calcium concentrations in the millimolar range
upon channel opening,24 suﬃcient to activate PAD activity.23 In
addition, one can speculate that the PADs’ calcium dependency
may be altered by speciﬁc PTMs or via the interaction of
binding proteins. In this regard, it was recently shown that
antibodies, isolated from patients with rheumatoid arthritis, can
bind and activate PAD4 by lowering the concentration of
calcium required for activity.25
Figure 5. Sequence alignment of human PAD family members. Catalytic residues are highlighted with red asterisks below the alignment. The
sequence alignment was generated using Clustal Omega and visualized using Espript 3.0.229 The consensus sequence is abbreviated as follows:
uppercase letters indicate identical residues, lowercase letters indicate consensus level >0.5, “!” represents any conserved residue of isoleucine (I) or
valine (V), “$” represents any conserved residue of leucine (L) or methionine (M), “%” represents any conserved residue of phenylalanine (F) or
tyrosine (Y), and “#” represents any conserved residue of asparagine (N), aspartate (D), glutamine (Q), or glutamate (E). The relative accessibility
of each residue is depicted below the consensus motif: blue indicates accessible residues, cyan marks intermediately accessible residues, white stands
for buried residues, and red indicates that the accessibility is not predicted.
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2.2.3. PAD Substrate Recognition. In contrast to other
members of the guanidino-group-modifying pentein family
such as ADI and DDAH, where peptidyl arginine is occluded
from the solvent by a loop closed over the active site, PAD4
substrate binding occurs at the molecular surface of the
enzyme, which is accessible for peptide/protein interactions.26
Thus, steric eﬀects provide at least a partial explanation for why
peptidyl arginine residues are recognized by PADs but not by
ADI or DDAH.21
The active site of PAD4 has a characteristic U-shaped tunnel
containing two entrance doors (Figure 9). This tunnel is also
found in other hydrolases of the pentein superfamily such as
DDAH.27 The “front door” is the actual substrate-binding site
accommodating the arginine side chain residue and derived
inhibitors, while the “back door” provides solvent access
through a highly polar tunnel connected to the base of the
active site. This narrow solvent channel presumably allows the
ammonia generated by the hydrolysis of arginine to diﬀuse
away and provide access for a water molecule for the
subsequent hydrolytic phase of the reaction to occur.28 As a
result, the access of other small molecules is restricted and
thereby prevents their reaction with the S-alkylthiouronium
intermediate during enzyme catalysis (see below), only allowing
Table 1. Rate Constant for PAD1-Catalyzed (kcat at pH 7.6)
and Noncatalyzed (knon at pH 7) Citrullination Reaction
type rate constant half-life
knon 5.3 × 10
−13 s−1 ∼42000 years
kcat 0.45 s
−1 1.54 s
Figure 6. Surface representation of the dimeric PAD4 C645A mutant
bound to the substrate BAA (PDB code 1WDA). (A) PAD4 exists as a
head-to-tail dimeric protein that comprises three domains as indicated
for one protomer. (B) The catalytic sites of both protomers are located
on the same dimer face and are separated by ∼65 Å. Abbreviation: Ig
subdomain, immunoglobulin-like subdomain.
Figure 7. Domain organization and calcium-binding sites of the PAD4 C645A protomer bound to the substrate BAA (PDB code 1WDA). The
structural elements are color coded according to Figure 6. The insets on the right depict two orientations of the PAD4 active site bound to BAA,
highlighting critical residues for substrate binding and catalysis. Polar contacts of <3.5 Å are represented as dashed lines.
Figure 8. The image on top represents the structure of PAD4 without
Ca2+ (blue) (PDB code 1WD8) superimposed onto the structure of
PAD4 with Ca2+ (orange) (PDB code 1WD9). The image on the
bottom depicts the structure of apoPAD2 without Ca2+ (gray) (PDB
code 4N20) overlaid onto the structure of holoPAD2 F221/222A
mutant with Ca2+ (purple) (PDB code 4N2C). The movements of
active site residues (bold) are highlighted as dashed lines. Ca2+ ions are
illustrated as green spheres, whereas active site residues are shown as
sticks.
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water to enter the active site. Interestingly, in related
amidinotransferases that do not utilize a hydrolytic mechanism
but transfer the activated amidine via a reactive cysteine
thiouronium intermediate onto their respective substrate
molecule such as glycine, the amidine-donor arginine substrate
occupies a position similar to that of the back door solvent
channel in PAD4.18c This observation raises the possibility that
the solvent channel in PAD4 and related hydrolases is a
vestigial substrate-binding site that is retained in amidino-
transferases from a common promiscuous ancestor.18c
Although the front door in PAD4 represents the major site
of inhibitor binding, it has been proposed that the back door
solvent channel might represent an alternative target for
inhibitor development.29
The structure of PAD4 bound to benzoyl-L-arginine amide
(BAA), a small-molecule mimic of peptidyl arginine, illustrates
key residues that are important for substrate recognition
(Figure 7). For example, aspartates D473 and D350 form two
bidentate salt bridges with the substrate guanidinium group,
positioning it for nucleophilic attack by C645. Notably, C645
and H471, which are involved in general acid/base catalysis, are
located on opposite sides of the guanidinium carbon center.
The aliphatic portion of the substrate arginine side chain is
clamped between W347 and V469 via hydrophobic inter-
actions. W347, along with R372, also appears to be a key player
in generating a catalytically competent active site since
mutation of either residue decreases activity to near background
levels.30 In the case of W347, this eﬀect is best interpreted by
the importance of this large hydrophobic side chain forming the
wall of the substrate-binding pocket. Although R372 does not
directly hydrogen bond to the substrate, except for a water-
mediated interaction, it directly interacts with D345 and E351,
which binds Ca2 and is close to the active site residue D350.
Therefore, R372 is critical for maintaining the structural
organization of the active site, but plays only a minor role in
substrate binding.
As mentioned above, PAD4 is highly selective for peptidyl
arginine substrates over nonpeptidyl arginine. This observation
can be rationalized by the engagement of the peptide backbone.
Speciﬁcally, the main chain carbonyl oxygen of the preceding
N-terminal residue and the arginine backbone carbonyl oxygen
atom form hydrogen bond interactions with the side chain of
R374 (see Figure 7), thereby conferring speciﬁcity toward
peptidyl arginine as opposed to free arginine, which lacks these
amide bonds.21 Consistent with this residue being important
for substrate recognition, mutation of R374 to alanine results in
a ∼20−50-fold reduction in enzymatic activity.31 The crystal
structures of PAD4 bound to several histone substrate peptides
further conﬁrmed this observation and revealed that the great
majority of contacts occur between the backbone carbonyl
groups of the peptide and the side chains of residues
surrounding the active site, i.e., Q346, W347, R372, and
R374 (Figure 10).31
The lack of signiﬁcant contacts between the enzyme and side
chains of the substrate may explain why sequence-speciﬁc
substrate recognition elements have been diﬃcult to identify.
While it was suggested that PAD4 recognizes ﬁve successive
residues with the consensus sequence of ΦXRXX, where Φ
Figure 9. Top view of the PAD4 C645A mutant bound to BAA
colored according to its electrostatic surface potential, highlighting two
connected cavities that form a continuous tunnel (orange rod) of ∼21
Å (PDB code 1WDA). The lower image illustrates the side view of the
active site cavity (front door), occupied by BAA, and the back door
tunnel, presumably involved in incoming water channeling and
ammonia (product) extrusion.
Figure 10. PAD4 (orange) bound to histone H3 peptide (gray) (PDB code 2DEW). Waters are depicted as red spheres. Adapted with permission
from ref 31. Copyright (2006) National Academy of Sciences, U.S.A.
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denotes amino acids with small side chain moieties and X
denotes any amino acid, it is evident from both the lack of
strong sequence speciﬁcity and the available PAD4 crystal
structures that there are no obvious substrate-speciﬁcity
determinants apart from the arginine-binding site.31 These
structures do, however, indicate that PAD4 peptide substrates
adopt a β-turn-like conformation in which the peptide
backbone is kinked to allow proper penetration of the arginine
side chain into the deep active site cavity. Therefore, in contrast
to most histone-modifying enzymes that interact extensively
with their peptide ligands and recognize their substrates in a
sequence-speciﬁc manner, the PADs likely modify exposed
arginine residues that can adopt the type of β-turn-like structure
described above.32 Thus, the enzyme has a fairly broad
sequence speciﬁcity and could target multiple arginine sites in
histones. However, speciﬁcity may be provided by controlling
access of the enzyme to a limited subset of arginine residues in
higher order chromatin structures, by crosstalk with other
PTMs, or through cooperation of PAD4 with additional factors.
In this respect, the Ig-like domains might also contribute to
substrate selection. For example, the binding aﬃnity between
PAD4 and HDAC1 was decreased by 3.3-fold upon
introduction of an autocitrullination-mimicking glutamine
residue at position R123, while there was no eﬀect on the
PAD4−H3 interaction.30b
2.2.4. Proposed Catalytic Mechanism of PADs. On the
basis of the available crystal structures and biochemical studies,
the following catalytic mechanism has been proposed (Figure
11).21,33 Brieﬂy, PAD4 catalyzes arginine citrullination by using
a nucleophilic cysteine residue that forms a covalent reaction
intermediate, which is hydrolyzed by an incoming water
molecule. Substrate binding is initiated by strong electrostatic
interactions between D350 and D473, the two active site
aspartate residues that coordinate the guanidinium group. The
carboxylate of D473 binds to both terminal ω-nitrogens of the
guanidinium group, whereas D350 coordinates to one ω-
nitrogen and the δ-nitrogen. Consequently, the thiolate of the
active site cysteine, C645, is appropriately positioned to
promote nucleophilic attack on the guanidinium carbon,
which results in the formation of a covalent tetrahedral
intermediate. H471, which is located on the opposite side of
the guanidinium group, is thought to promote catalysis by
protonating the tetrahedral intermediate, either concomitantly
with nucleophilic attack by the active site cysteine or in a
stepwise fashion, thereby generating a better leaving group and
promoting cleavage of the scissile C−N bond. After the collapse
of this reaction intermediate, ammonia is released. Thereafter,
the covalent S-alkylthiouronium intermediate is subsequently
hydrolyzed by the attack of an H471-activated water molecule,
forming a second tetrahedral intermediate that collapses to
eliminate the C645 thiolate, ultimately generating citrulline.
Support for this mechanism comes from initial studies
conﬁrming that PADs are cysteine-dependent enzymes as
evidenced by the strong inhibition aﬀorded by iodoacetate or
PCMB and the requirement of a reducing agent such as DTT.34
Detailed mutagenesis, pH rate proﬁle, solvent isotope eﬀect,
and solvent viscosity eﬀect studies also support this
mechanism.33 In addition, several inhibitor-bound structures,
i.e., F-amidine (N-alpha-Benzoyl-N5-(2-ﬂuoro-1-Iminoethyl)-L-
Ornithine Amide), Cl-amidine (N-alpha-Benzoyl-N5-(2-
Chloro-1-Iminoethyl)-LOrnithine Amide), and TDFA (threo-
nine-aspartate-F-amidine) (see below),30a,35 are consistent with
the proposed mechanism.
Notably, PAD4 has a pH optimum of ∼7.6 and uses a reverse
protonation mechanism that is manifested by the high pKa of
the active site cysteine C645 (pKa ≈ 8.3); this pKa value was
measured by pH-dependent kinetic inactivation studies using
the cysteine reactive compound iodoacetamide.33a In addition,
Figure 11. Proposed catalytic mechanism for PAD enzymes.
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H471 has to be protonated for eﬃcient catalysis to take place.
However, the pKa for H471 is ∼7.3 and is therefore below the
pH optimum of the enzyme. Consequently, there is just a small
pH window for optimal PAD4 activity, indicating that only a
fraction of PAD4 (∼15%) exists in the proper deprotonated
C645-thiolate and protonated H471-imidazolium forms at the
pH optimum. Mechanistic studies on PAD1 and PAD3 have
conﬁrmed that they also proceed through a similar reverse
protonation mechanism.33b Interestingly, however, PAD2
appears to use a substrate-assisted mechanism, in which the
positively charged substrate guanidinium promotes catalysis by
depressing the pKa of the nucleophilic cysteine.
36 This
conclusion was mainly based on pH-dependent inactivation
studies by comparing the guanidinium group mimicking
compound 2-chloroacetamidine with the neutral iodoaceta-
mide. Consistent with PAD4, iodoacetamide inactivation
revealed a pKa of 8.2 for the active site cysteine, whereas the
use of 2-chloroacetamidine yielded a pKa value of 7.2 for the
same cysteine. Therefore, it was proposed that PAD2, like
DDAH,37 uses a substrate-assisted mechanism rather than a
reverse-protonation mechanism.36
2.3. Do PADs Function as “Demethyliminases”?
There has been some controversy regarding whether the PADs
act on methylated arginine residues. One study claimed that
PAD4 catalyzes the conversion of monomethylarginine into
citrulline.38 However, the “demethylimination” reaction occurs
at rates that are several orders of magnitude (100−10000-fold)
slower for peptide substrates containing either a single
monomethyl or a single asymmetrically dimethylated arginine
residue than the actual deimination reaction of unmodiﬁed
arginine residues.19 Two further studies report that methylation
of the guanidinium group even prevents and inhibits
citrullination.39 Using synthetic peptides that contain methy-
lated arginine residues, neither human PAD2, PAD3, PAD4,
and PAD6 enzymes nor PADs present in mouse tissue extracts
are capable of generating peptidyl citrulline or peptidyl
methylcitrulline from either mono- or dimethylated peptidyl
arginine.39b
Notably, structural comparison of the active site cavity of
PAD4 with DDAH further revealed striking diﬀerences that
might explain the individual substrate preferences (Figure 12A).
DDAH is very selective for asymmetric dimethylated non-
peptidyl arginines to ensure that DDAH only hydrolyzes
methylated arginine, which acts as a physiological inhibitor of
nitric oxide synthase, while sparing unmodiﬁed arginine, which
is the substrate for nitric oxide synthase.27b The active site
residues in PAD4 and DDAH are highly conserved; however,
PAD4 has a much smaller active site pocket, containing an
aspartate at the bottom. This aspartate directly forms a
bidentate hydrogen bond to the substrate guanidinium group,
whereas DDAH possesses a lysine at the corresponding
position that bends away from the substrate-binding site,
thereby forming a larger active site pocket that can
accommodate methylated arginine residues or even an
iminopentyl group as illustrated in Figure 12A.27b,40 In the
case of PAD4, a methylated guanidinium group would clash
with the active site aspartate residues, thereby preventing
proper substrate alignment (Figure 12B). Taken together,
methylarginines are unlikely to represent physiologically
relevant substrates, and it is more likely that arginine
Figure 12. Comparison of PAD4 and DDAH active site pockets. (A) Active site of PAD4 with bound BAA (left side) (PDB code 1WDA), bovine
DDAH with bound citrulline abbreviated as Cit (middle panel) (PDB code 2C6Z), and human DDAH with bound N5-(1-iminopentyl)-L-ornithine
abbreviated as LN6 inhibitor (right side) (PDB code 3P8P). All protein structures are colored according to their electrostatic surface potential. (B)
Bidendate recognition of the substrate arginine guanidinium group (gray) by the carboxyl groups of PAD4 (orange, PDB code 1WDA) D473 and
D350, left panel. Methylation of the arginine guanidinium group would disfavor and preclude tight interactions with the aspartate residues, right
panel.
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methylation antagonizes citrullination as proposed by Cuthbert
et al. and Kearney et al.19,28,41 Notably, since citrulline residues
are not methylated by the PRMTs, these two modiﬁcations are
mutually exclusive.
2.4. Is Protein Citrullination a Reversible Modiﬁcation?
Although many histone PTMs are reversibly regulated by the
action of writers and erasers, there is currently no known
citrulline eraser. However, the level of H3 citrullination is
dynamically controlled, indicating that citrulline deposition is
transient during gene expression.41 For example, PAD4 was
shown to be recruited to the pS2 promoter and to citrullinate
histone H3 when MCF-7 cells were stimulated with estrogen.
Notably, this promoter region elicits a strong signal for H3
citrullination 40 min poststimulation; however, after an
additional 10 min, the amount of H3 citrullination drops
rapidly to its original levels, observed before estrogen
stimulation, suggesting that a “decitrullinase” may exist.41
While the dynamic nature of citrulline marks could be caused
by histone tail clipping, epitope occlusion, or nucleosome
displacement,42 the existence of a decitrullinase remains a
formal possibility.
Precedence for such a reaction comes from the urea cycle
where nonpeptidyl citrulline is converted to free arginine by the
combined actions of argininosuccinate synthetase and argini-
nosuccinate lyase (Figure 13).43 Argininosuccinate synthetase
catalyzes the conversion of L-citrulline into argininosuccinate
(Figure 13A). The ﬁrst step involves the activation of the urea
oxygen of citrulline via covalent modiﬁcation by an adenosine
monophosphate (AMP) moiety.43b Subsequently, the α-amine
of aspartate acts as the nucleophile and attacks the carbon
center of the urea, thereby displacing the AMP moiety and
generating argininosuccinate. Thus, argininosuccinate synthe-
tase converts the neutral urea of citrulline into a guanidinium
connected to succinate. To remove the succinate moiety, the
second enzyme, argininosuccinate lyase, catalyzes C−N bond
cleavage with the subsequent release of fumarate and arginine
(Figure 13B). The catalytic mechanism proceeds through the
deprotonation of the β-carbon of succinate, thereby forming a
highly reactive carbanion intermediate.43a Redistribution of the
negative charge into the carboxylate group generates the aci-
carboxylate intermediate, which provides the driving force for
the cleavage of the fumarate group. Protonation of the
guanidinium by a general-acid catalyst further facilitates the
reaction.
Whether a similar set of enzymes might act on peptidyl
citrulline is unclear, but this mechanism provides the principle
Figure 13. (A) Active site of argininosuccinate synthetase with bound citrulline, aspartate, and ATP (PDB 1J1Z) and proposed mechanism. (B)
Active site of the argininosuccinate lyase homologue δ crystalline T161D mutant with bound argininosuccinate highlighted in gray (PDB 1TJW) and
proposed mechanism. Abbreviations: Cit, citrulline; Asp, aspartate; ATP, adenosine triphosphate; PPi, pyrophosphate; AMP, adenosine
monophosphate, AS, argininosuccinate; H−B, general acid.
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requirements for promoting a decitrullination reaction, i.e.,
covalent modiﬁcation of the urea oxygen atom coupled to
incorporation of ammonia, donated by an aspartate-,
glutamate-, or glutamine-dependent enzyme. Thus, one could
imagine a variety of alternative strategies to achieve the same
outcome, including activation by phosphorylation to generate a
better leaving group and cleavage of the phospho intermediate
by ammonia.
2.5. Inhibitors and Chemical Probes of PADs
2.5.1. Reversible Inhibitors of PADs. In recent years,
numerous PAD inhibitors have been developed (Figures
14−16). Initial studies focused on reversible inhibitors (Figure
14). For example, Taxol (the generic name is paclitaxel)
inhibited PAD4 in the low millimolar range.44 The authors
suggested that paclitaxel acts as a noncompetitive inhibitor of
PAD4, since the KM was not aﬀected while the Vmax was
reduced. Given the absence of citrullination when testing
methylated arginine residues as PAD4 substrates (see above),
Hidaka and colleagues also determined whether these arginine
derivatives can inhibit PAD4 activity.39a They observed that
both benzoyl-Nω-monomethylarginine (Bz-MMA) and benzo-
yl-Nω,Nω-dimethylarginine (Bz-ADMA) inhibit the enzymatic
activity of PAD4. However, these compounds are relatively
modest inhibitors. The IC50 value of Bz-ADMA was estimated
to be ∼400 μM, whereas the IC50 value for the weaker inhibitor
Bz-MMA was not determined.
Employing a PAD4-targeted activity-based protein proﬁling
(ABPP) inhibitory screen (described below), Thompson and
colleagues screened a small library of therapeutics used for the
treatment of rheumatoid arthritis (RA).45 Given that
streptomycin contains two guanidinium groups, the authors
also considered the possibility that streptomycin might act as an
alternative substrate; however, streptomycin was not deimi-
nated by PAD4. In general, the potency of the tested
compounds is relatively weak, ranging from low millimolar to
mid-micromolar. Notably, streptomycin is a competitive
inhibitor of PAD4, with a Ki value of ∼0.56 mM, and the
tetracycline derivative minocycline was shown to be a mixed-
type inhibitor with a Ki value of ∼0.63 mM. A similar
compound, chlortetracycline, which only diﬀers from minocy-
cline by the addition of a hydroxyl and methyl group at position
6 and a chloro group replacing the dimethylamine moiety at
position 7, is a signiﬁcantly more potent inhibitor (Ki value of
∼0.11 mM). Kinetic studies further revealed that chlortetracy-
cline is also a mixed inhibitor, similar to minocycline. Although
the detailed mechanism of inhibition and the speciﬁc binding
site of the tetracycline derivatives are currently unknown, the
tetracycline scaﬀold might be exploited in the future design of
reversible PAD4 inhibitors. Although it is tempting to speculate
that the eﬃcacy of the most eﬀective PAD4 inhibitors,
identiﬁed in this screen, minocycline and other tetracycline
derivatives, is due in part to their ability to inhibit cellular
PAD4, we note that it is not clear whether the high
concentrations of compound needed to inhibit PAD4 in vitro
could be achieved systemically. Additionally, these compounds
are known to inhibit a wide range of other enzymes, including
collagenase, poly-ADP-ribose polymerase-1 (PARP-1), Arach-
idonate 5-lipoxygenase, and several cysteine proteinases, that
may also contribute to their eﬃcacy as RA therapeutics and
their ability to impair neutrophil chemotaxis and act as anti-
inﬂammatory agents.
In addition to these compounds, the guanidine derivative 6
(Figure 14) was recently shown to inhibit PAD4 activity (8%
inhibition at 1 μM and 36% inhibition at 10 μM).46 The
authors claim that 6 most likely acts through a noncovalent
Figure 14. Reversible PAD inhibitors. The presence of a guanidine group is highlighted in blue.
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mechanism to block the activity of PAD4; however, the detailed
mode of action and inhibition studies were not performed by
the authors. Ferretti and colleagues also recently described a
novel PAD inhibitor (7) comprising a 3,5-dihydroimidazol-4-
one ring that replaces the acyclic guanidine moiety present in
arginine residues.47 This new small-molecule PAD3 inhibitor
was reported to show inhibition at 100 nM using cell extracts
containing recombinant PAD3. The high potency of this
inhibitor is rather surprising since the pKa of acylguanidines is
typically 4−5 orders of magnitude lower than that of the
corresponding guanidines.48 Additionally, it is noteworthy that
this strong level of inhibition has not been replicated in our
hands.
More recently, an ABPP-based inhibitor screening strategy to
identify inhibitors that target the calcium-free form of PAD2
identiﬁed ruthenium red (8) as a PAD2 inhibitor.49 This
compound preferentially binds the apoenzyme with a Ki of 17
μM for PAD2 and was shown to be competitive with calcium,
presumably binding at the calcium 3, 4, and 5 sites. Ruthenium
red is also a potent inhibitor for the other PAD isozymes with
apparent Ki values of 30 μM for PAD1, 25 μM for PAD3, and
10 μM for PAD4. The ability to identify inhibitors targeting the
apo form of the PADs holds great promise for developing
highly potent non-active-site-directed reversible inhibitors
targeting the PADs.
Lewis and colleagues recently described a highly potent and
reversible inhibitor that shows remarkable selectivity for
PAD4.50 In this study, the authors screened a DNA-encoded
small-molecule library for PAD4 inhibitors in the absence and
presence of calcium. Optimization of the primary hits yielded
GSK199 (9) and GSK484 (10) (Figure 15A). Notably,
inhibition is calcium dependent for both compounds. In the
absence of calcium, GSK199 and GSK484 inhibit PAD4 with
IC50 values of 200 and 50 nM, respectively, while in the
Figure 15. (A) Reversible, mixed-type PAD4 inhibitors. Kis is the dissociation constant for the enzyme−inhibitor complex. (B) Crystal structure of
PAD4 bound to inhibitor 9, GSK199 (PDB code 4X8G). GSK199 (gray) directly interacts with active site residues H471 and D473, and is further
stabilized by binding to F634 and N588. Hydrogen bonds of <3.5 Å are represented as dashed black lines. (C) The image on the left side depicts the
structure of PAD4 (orange) bound to inhibitor GSK199 (gray, PDB code 4X8G) superimposed onto the structure of PAD4 (green) bound to BAA
substrate (green stick model, PDB code 1WDA). Residues 633−640 (red, denoted by α) of PAD4 bound to BAA adopt an α-helical conformation,
while residues 633−645 (yellow, denoted by β) of PAD4 bound to GSK199 form an antiparallel β-sheet. The image on the right side compares the
binding sites of BAA (green) and GSK199 (gray) mapped onto the structure of PAD4 (PDB code 1WDA), colored according to its electrostatic
surface potential.
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presence of calcium their potencies were reduced by ≥5-fold.
Interestingly, detailed kinetic analysis demonstrated a mixed
mode of inhibition for these compounds and showed that they
possess more than 35-fold selectivity for PAD4 compared to
the other PADs. The crystal structure of PAD4 bound to
GSK199 revealed that the inhibitor directly interacts with the
active site residues D473 and H471 (Figure 15B). Comparison
of inhibitor- and substrate-bound PAD4 shows that an active
site α-helical region, present in the substrate-bound form,
adopts a new conformation and is reordered to form a β-hairpin
in the inhibitor-bound structure (Figure 15C). In addition,
detailed inspection of the orientation of GSK199 highlights a
partial overlap between the aminopiperidine group of 9 with
the substrate guanidinium group. However, in contrast to the
substrate side chain that occupies the front door channel, the
benzimidazole and pyrrolopyridine moieties of 9 protrude out
into the back door solvent exchange channel (Figure 15C).
Notably, these compounds bind a form of PAD4 that lacks
calcium at the Ca2 site, mimicking our calcium titration data
with PAD2, and again highlighting the importance of Ca2 for
generating a catalytically competent conformation. Overall,
these inhibitors represent a great example of a successful
combination of high-throughput screening eﬀorts with detailed
biochemical and structural characterizations to yield novel
compounds with potential therapeutic applications.
2.5.2. Irreversible, Covalent Inhibitors of PADs. Over
the past several years, major progress has been made in
generating irreversible inhibitors targeting the PADs (Figure
16A). Initial studies suggested that 2-chloroacetamidine, having
a guanidinium-like amidinium group, represented a suitable
candidate for PAD inhibition.51 In fact, 2-chloroacetamidine is a
modest PAD4 inactivator, which blocks enzyme activity in a
time-dependent manner, characteristic of a covalent inhibitor.
Inspired by BAA, one of the best small-molecule PAD4
substrates, the Thompson group installed reactive electrophilic
ﬂuoroacetamidine or chloroacetamidine warheads onto the
BAA scaﬀold.35a,52 The generated compounds, denoted as F-
amidine or Cl-amidine, respectively, were the ﬁrst highly potent
PAD4 inhibitors. In the context of BAA, this haloacetamidine-
based warhead is targeted to the active site of PAD4, where it
Figure 16. (A) Covalent, irreversible inhibitors of the PADs. The presence of an amidine group is highlighted in blue. The potency toward the
individual PAD isozymes is represented below the compounds. (B) Potential mechanisms of PAD inactivation by chloroacetamidine-based
inhibitors.
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reacts with C645 to form a stable thioether adduct. Indeed, in
vitro studies revealed that both Cl-amidine and F-amidine act as
mechanism-based inhibitors that irreversibly inactivate PAD4
and other PAD isozymes in a calcium-dependent manner via
the speciﬁc modiﬁcation of C645, the active site cysteine.35a,52
The alkylation of C645 proceeds through one of two
potential mechanisms.53 In the ﬁrst mechanism, C645 directly
displaces the halide through an SN2 mechanism. Alternatively,
inactivation could proceed via a multistep mechanism that
involves nucleophilic attack of the cysteine thiolate on the
amidinium carbon, forming a tetrahedral intermediate that
mimics the initial tetrahedral intermediate formed during
substrate hydrolysis. The protonation of the tetrahedral
intermediate by H471, acting as a general acid, is thought to
stabilize the rather unstable hemi-iminal tetrahedral intermedi-
ate such that it is long enough lived to undergo an
intramolecular halide displacement reaction, which generates
a three-membered sulfonium ring. Although the proposed
dicationic intermediate depicted in Figure 16B is unprece-
dented in the literature, dianionic intermediates have been
described.43a Regardless of the speciﬁc mechanism, formation
of the three-membered sulfonium ring ultimately induces the
collapse of the tetrahedral intermediate, leading to a 1,2-shift
that generates a thioether linkage, whose existence has been
veriﬁed crystallographically (Figure 17).35a Although, in
principle, both mechanisms are plausible, the bell-shaped pH
inactivation rate proﬁles observed for both F-amidine and Cl-
amidine strongly support the second inactivation mechanism,
especially the importance of H471 as a general-acid catalyst.
Notably, the pH-dependent rate of inactivation correlates with
the pKa values obtained for H471 and C645, indicating that
these two residues likely possess a critical role not only for
substrate turnover but also for enzyme inactivation by
haloacetamidine-containing compounds.53 The second mecha-
nism also accounts for the otherwise poor leaving group
potential of the ﬂuoride. Furthermore, crystal structures of
PAD4 bound to several inhibitors (PDB codes 2DW5, 3B1T,
3B1U, and 4DKT) show that the histidine (H471) nitrogen
atom Nδ1 directly points toward the Nω atom of the amidine
inhibitor, as exempliﬁed by the PAD4·F-amidine complex,
where one can observe a 2.9 Å distance between Nδ1 from
H471 and Nω from the amidine group of the inhibitor. More
recently, however, a computational study of the PAD4
inactivation mechanism suggested that proton donation to
the departing halide may, alternatively, account for the loss of
reactivity at higher pH values.54 Discriminating between these
two potential mechanisms will undoubtedly be the subject of
future research.
Cl-amidine and 2-chloroacetamidine possess similar maximal
rates of inactivation (i.e., kinact). Cl-amidine, however, is a far
more potent inhibitor due to increased binding energy. Thus,
selective enzyme inactivation is driven in part by the aﬃnity of
the enzyme for the inhibitor. Further exploration of the Cl-
amidine scaﬀold resulted in the identiﬁcation of more potent
PAD inactivators, such as o-carboxyl-Cl-amidine (14).30a
Structural analysis of this compound bound to PAD4 revealed
that the o-carboxylate forms a direct hydrogen bond with the
indole NH of W347 and a water-mediated hydrogen bond with
the side chain of Q346, which might explain the enhanced
potency of 14 compared to Cl-amidine (Figure 17B).30a
Additional selectivity studies revealed that 14 preferentially
inactivates PAD1. The selectivity for PAD1 inhibition is 8-, 10-,
and 3-fold higher than that obtained for PAD2, PAD3, and
PAD4, respectively.30a
Using a solid-phase peptide library approach, the Thompson
group also identiﬁed a novel PAD4-selective inhibitor that
consists of a tripeptide comprising threonine, aspartate, and the
warhead-containing F-amidine residue (TDFA).35b TDFA is
highly selective for PAD4 (up to 65-fold) with excellent in vivo
potency.35b The crystal structure of TDFA bound to PAD4
further revealed that the carboxylate group from the TDFA
aspartate residue directly interacts with the amide nitrogen of
the glutamine residue Q346 of PAD4 (Figure 17 B).
Interestingly, the TDFA carboxylate adopts a position similar
to that of the o-carboxylate group in o-Cl-amidine as well as the
carbonyl oxygen of T7 in the H3 substrate (Figures 10 and 17),
but does not directly hydrogen bond with the side chain of
W347.35b The negative charge of the carboxylate might further
enhance inhibitor binding through long-range electrostatic
interactions with residues R374 and R639.35b
Despite the availability of several PAD inhibitors, Cl-amidine
is still the most widely used compound and serves as a
benchmark to estimate the potency of novel inhibitors.
Although Cl-amidine was shown to reduce protein citrullina-
tion in cell and animal studies, and ameliorate disease severity
in several animal models (see below), there are still several
obstacles remaining to be solved before its potential clinical use,
including a short in vivo half-life, poor bioavailability, and,
because Cl-amidine is an irreversible inhibitor, the potential for
oﬀ-target eﬀects.55 Therefore, eﬀorts have been undertaken to
generate more stable Cl-amidine derivatives that resist
proteolysis in vivo. To this end, the D-amino acid derivative
Figure 17. Crystal structures of PAD4 with inhibitors bound. (A)
Schematic overview of PAD4 (blue) bound to a peptidyl substrate
(gray) (left panel). Structural alignment of inhibitors bound to the
active site of PAD4. The histone H3 peptide (sequence TARKS)
bound to PAD4 (gray) (PDB code 2DEW) is included to compare the
substrate-binding site. The Cl-amidine (magenta) (PDB code 2DW5),
o-Cl-amidine (yellow) (PDB code 3B1T), and TDFA (red) (PDB
code 4DKT) structures are aligned accordingly, including the
depiction of critical PAD4-interacting residues. (B) Close-up view of
PAD4 with bound inhibitors, highlighting critical inhibitor backbone
interactions with PAD4 residues shown as dashed lines. Interactions
between the amidine group as well as the α-amine of the inhibitor and
PAD4 are omitted for clarity.
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of Cl-amidine (D-Cl-amidine) has been synthesized.55 D-Cl-
amidine is slightly less potent in vitro and preferentially
inactivates PAD1. The inhibition of PAD4 by D-Cl-amidine is
consistent with the observation that PADs are also active on D-
arginine derivatives at a rate that is ∼5-fold weaker than that for
the L-isomer.56 However, D-Cl-amidine is equally potent in cells
as compared to L-Cl-amidine and exhibits better pharmacoki-
netics, presumably due to decreased proteolysis.55
Since Cl-amidine is a highly hydrophilic compound that
readily dissolves in water, Wang and colleagues tried to increase
the hydrophobicity and thereby bioavailability of Cl-amidine.57
Speciﬁcally, they synthesized a diverse panel of molecules, all
comprising the Cl-amidine scaﬀold, ﬂanked by alternative
hydrophobic groups. The most potent inhibitor (16) contained
a Cα-amide-methylbenzene as well as an Nα-amide-dimethyl-
naphthylamine moiety attached to the regular Cl-amidine
scaﬀold. Compound 16 showed similar in vitro inhibition
values (IC50 = 1−5 μM) compared to Cl-amidine (IC50 = 5
μM); however, inhibition of cellular proliferation was increased
by ∼50-fold, most likely due to an improvement in cell
permeability.57
Another interesting Cl-amidine derivative is BB-Cl-amidine
(17), which contains a C-terminal benzimidazole and an N-
terminal biphenyl moiety. The increased hydrophobicity of this
compound also improves its cellular potency, bioavailability,
and in vivo half-life.58 BB-Cl-amidine exhibits similar in vitro
potencies and selectivities compared to Cl-amidine. However,
the cellular potency of BB-Cl-amidine is increased by more
than 20-fold; the EC50 value is 8.8 μM versus >200 μM for Cl-
amidine when tested against U2OS osteosarcoma cells, a
PAD4-expressing cell line.
Projecting forward, with the exception of TDFA and
GSK199, most of the currently available compounds are pan
PAD inhibitors that block all of the active PAD isozymes with
similar potencies. Thus, the identiﬁcation of isozyme-selective
PAD inhibitors remains of crucial importance, and will facilitate
the discovery of the individual contributions of PAD isozymes
to both cellular physiology and disease.
2.5.3. Chemical Probes for the PADs. Given the high
potency and ability to irreversibly modify PAD4, as well as the
fact that F-amidine and Cl-amidine selectively modify the
active, calcium-bound, form of PAD4, these compounds were
adapted for use as ABPP reagents. The ﬁrst synthesized PAD-
selective ABPP was rhodamine-conjugated F-amidine (RFA,
19; Figure 18A).59 This compound retains the F-amidine
scaﬀold but is linked to a ﬂuorescent reporter tag (rhodamine)
Figure 18. ABPP probes for PADs. (A) Structures of PAD-selective probes. The amidine group is highlighted in blue, whereas the reporter tags
(rhodamine or biotin) are marked in red. (B) Schematic overview of ﬂuorescence polarization assay using the PAD4-speciﬁc RFA probe.
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via a p-benzylic triazole group. Preliminary studies conﬁrmed
that this ﬂuorescently tagged PAD4-targeted ABPP preferen-
tially labels the calcium-bound, active, form of PAD4 and does
not modify a C645S mutant.59 The probe shows potency equal
to that of the non-reporter-tagged F-amidine, indicating that
the reporter group does not interfere with enzyme binding. In
addition, a biotinylated version of F-amidine (BFA, 20) was
synthesized to isolate endogenous PADs.60 The BFA probe
further contains a TEV (tobacco etch virus) cleavage site to
release bound PAD4 under gentle conditions. This probe was
used to coisolate PAD4-interacting proteins from MCF7 cells.
While the probe selectively targets endogenous PADs, it was
also able to copurify several known PAD4-associated proteins,
including p53, HDAC1, and histone H3, indicating that this
approach might be used to identify novel PAD4-binding
proteins.60 Therefore, these PAD-speciﬁc ABPPs represent
valuable tools that can be used to label PAD4 in cells, as well as
to enrich active PAD4- and PAD4-interacting proteins.
In addition to their potential use in targeted proteomic
studies and activity-based protein proﬁling applications, these
probes have been used as the basis for developing a number of
inhibitor screening platforms. To this end, the Thompson
group developed a screening assay that relies on RFA to
identify novel PAD inhibitors from diverse chemical libraries in
a gel-based format.45 RFA can also be used to measure changes
in PAD activity as a function of added inhibitor in a plate-based
assay that is compatible with large compound libraries used in
high-throughput screening (HTS) approaches by monitoring
the changes in ﬂuorescence polarization evoked by probe
labeling of the enzyme (Figure 18B). The basis of this assay
comes from the fact that when the ﬂuorescent group is excited
with polarized light, the RFA−PAD4 complex will rotate slowly
and therefore emit highly polarized light. Conversely, free RFA
rotates faster and emits nonpolarized light. If an inhibitor is
bound to PAD4, it will compete with RFA for enzyme
interaction, thereby yielding a low ﬂuorescence polarization
signal. Using this ﬂuorescence polarization activity-based
protein proﬁling (ﬂuopol-ABPP)-based HTS assay, the
Thompson group screened the NIH validation set, comprising
2000 compounds, and identiﬁed streptonigrin (18) as a potent
and selective (>35-fold selective for PAD4) PAD4 inactivator.61
This compound shows time-dependent enzyme inactivation
and acts as an irreversible PAD4 inhibitor (kinact/KI = 4.4 × 10
5
min−1 M−1). The detailed mode of inactivation is still, however,
unknown.62 In addition to its in vitro activity, streptonigrin also
inhibits the histone citrullination activity of PAD4 in HL-60
granulocytes and MCF7 cells.61 Unfortunately, however,
streptonigrin has a number of oﬀ targets leading to pleiotropic
eﬀects on cell viability and signaling, thereby limiting its utility
as a probe of PAD4 activity.
More recently, the Thompson group adapted this ﬂuopol-
ABPP-based HTS approach to identify PAD2 inhibitors. Here,
the authors hypothesized that by lowering the concentration of
calcium in the reaction mixture they might identify compounds
that speciﬁcally bind to the apo, calcium-free form of the
enzyme. Using this biased assay format, Lewallen et al. screened
the LOPAC collection of pharmacologically active compounds
and identiﬁed ruthenium red as the ﬁrst calcium competitive
inhibitor for the PADs.49 Although this compound shows
limited utility as a cellular probe of PAD activity, its discovery
does demonstrate that it is possible to identify potent non-
active-site-targeted reversible PAD inhibitors.
2.6. Physiological Roles of Histone Citrullination
2.6.1. Epigenetic Eﬀects of Histone Citrullination.
Currently, the known sites of histone citrullination have been
mapped to H2AR3,63 H3R2, H3R8, and H3R17,41 H3R26,41,64
and H4R338 (Figure 19). In addition, H4R17, H4R19, and
H4R23 can be citrullinated by PAD4 in vitro but have not been
found to be a target of citrullination in vivo.31 Histone
citrullination is associated with both transcriptional repression
and activation.38,41,64 For example, the citrullination of H3R17
by PAD4 at the estrogen receptor α (ERα)-regulated pS2
promoter was shown to correlate with transcriptional
repression by interfering with activating, PRMT4-mediated,
arginine methylation events.38,41 Moreover, p53-dependent
recruitment of PAD4 to the p21 promoter resulted in
citrullination of histone H3 and inhibition of gene tran-
scription.65 The function of PAD4 as a p53 corepressor is
further enhanced by direct interaction between the histone
deacetylase HDAC2, which also represses p53 target genes, and
PAD4.66 Exposure to genotoxic stress induced the release of
PAD4 from the p21 promoter, which is subsequently
derepressed by activating methylation of histone H3R17 by
PRMT4.65 PAD4 also mediates histone H3 citrullination on the
promoter of the OKL38 gene, thereby repressing the
expression of this pro-apoptotic tumor suppressor gene.67
However, following DNA damage, increased p53 binding and
histone arginine methylation, as well as a decrease in histone
citrullination on the OKL38 promoter, accompany the
activation of OKL38, suggesting a direct role of PAD4 and
p53 in the expression of OKL38.67
Citrullination of H3R8 following estrogen-induced activation
of PAD4 also correlates with target gene activation by
abolishing the H3K9me3-directed recruitment of HP1α to
ERα-dependent promoters.68 HP1α is a chromatin-binding
protein that speciﬁcally interacts with the H3K9me3 mark to
repress gene expression by inducing a heterochromatin-like
state that is refractory to high-level transcription. It was further
shown that methylation of H3R8 slightly reduces the binding of
the transcriptional repressor HP1α to H3K9me3.68 This
example of histone PTM crosstalk raises the interesting
possibility that diﬀerences in HP1α-binding aﬃnity to
H3K9me3 are caused by H3R8 methylation or citrullination,
thereby regulating the gradual activation of HP1α target genes
upon estrogen stimulation.
Figure 19. Citrullination sites in histone proteins. Color code: green,
gene activation; red, gene repression; yellow, gene activation or
repression, or unknown.
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Increased citrullination at H3R8 in peripheral blood
mononuclear cells also results in the activation of downstream
genes such as the cytokines TNFα and IL8, which ultimately
leads to inappropriate T-lymphocyte activation and uncon-
trolled immune response in multiple sclerosis.68 More recently,
PAD4 was shown to interact with TAL1, a transcription factor
that is essential for the generation of embryonic hematopoietic
stem cells.69 There, it was demonstrated that TAL1-bound
PAD4 acts as an epigenetic coactivator by competing with
PRMT6-mediated methylation of the repressive H3R2me2a
mark and thus increases IL6ST expression. Alternatively, TAL1-
recruited PAD4 can function as a corepressor by counteracting
the activating H3R17me2a mark by PRMT4, thereby inhibiting
the expression of the CTCF-encoding gene.
More recently, it was shown that PAD4 citrullinates a single
arginine residue, H1R54, within the DNA-binding site of
histone H1. Modiﬁcation of this residue results in H1
displacement from chromatin, thereby inducing global
chromatin decondensation in pluripotent cells.70 It was also
shown that PAD4 is expressed and active in murine embryonic
stem (ES) cells as well as reprogrammed induced pluripotent
stem (iPS) cells. Interestingly, the expression of PAD1, PAD2,
and PAD3, but not that of PAD6, is also observed in pluripotent
cells, indicating a potential function for these PADs in
pluripotency or cell diﬀerentiation as well.70 In these cells,
PAD4 plays a critical role in the pluripotency transcriptional
network by enhancing the expression of genes involved in stem
cell development and maintenance that can be inhibited by
addition of Cl-amidine. For example, PAD4 binds to the
promoter region of key stem cell genes such as Klf 2, Tcl1,
Tcfap2c, Kit, and Nanog, thereby activating their expression.70
Chromatin immunoprecipitation−quantitative polymerase
chain reaction (ChIP−qPCR) analyses revealed that the
association of H1 with chromatin at the regulatory regions of
Tcl1 and Nanog is low in pluripotent cells; however, upon Pad4
knockdown, it is signiﬁcantly enhanced. Moreover, mutation of
H1R54 to alanine impairs its interaction with nucleosomes,
supporting the critical role of this residue in nucleosome
binding. The citrullination of H1 induces chromatin decom-
paction and may enhance the accessibility of RNA polymerase,
transcription factors, and further histone-modifying enzymes.
The PAD4-induced open chromatin architecture is also
important for stem cell pluripotency during early mouse
embryogenesis and can be impaired by Cl-amidine and TDFA
treatment.70 The overexpression of PADs in multiple cancers
(see below) might induce a similar stem-cell-like state,
containing decondensed chromatin, and thereby promote
uncontrolled cell growth.71 Interestingly, Dwivedi and
colleagues recently observed that the citrullination of histone
H1 at arginine 54 is also critical for neutrophil extracellular trap
(NET) formation (see below) and represents an autoantibody
epitope in sera from patients with systemic lupus erythemato-
sus and Sjögren’s syndrome.72
PAD4 was long thought to be the only nuclear PAD and as
such was assumed to be responsible for all nuclear histone
citrullination events. Recent studies, however, indicate that this
is not the case and that PAD2 is also capable of citrullinating
histones.17b,64 For example, PAD2 expression was shown to be
upregulated by epidermal growth factor (EGF) stimulation in
mammary epithelial cells.17b There, nuclear PAD2 citrullinates
histone H3 at R2, R8, and R17. It was proposed that PAD2-
induced histone citrullination may play a regulatory role in the
expression of lactation-related genes during the diestrus phase
of the estrous cycle.17b
Moreover, citrullination of H3R26 by PAD2 at ERα target
genes has been linked to transcriptional activation of more than
200 genes.64 The presence of H3R26 Cit destabilizes the
nucleosome structure to allow for eﬃcient ER binding to
nucleosomal DNA.73 The altered nucleosome structure directly
correlates with estradiol administration. Hence, it was proposed
that, following estradiol exposure, ER directly or indirectly
recruits PAD2 to ER target genes where PAD2 then
citrullinates H3R26. The citrullinated H3 was postulated to
induce an altered conformation of the nucleosome, manifested
by core nucleosome particle protection size shifts from 149 to
125 bp upon H3R26 deimination, which allows for a more
stable interaction between ER and its nucleosomal ER-binding
sites.73 Interestingly, this arginine residue can also be
methylated, and these two modiﬁcations are inversely
correlated.41 It is also interesting to note that citrullination at
H3R26 strongly colocalizes with H3K27 acetylation in MCF-7
cells, thereby raising the possibility for crosstalk between these
two modiﬁcations.64
2.6.2. Epigenetic Eﬀects of Nonhistone Citrullination.
Apart from direct histone citrullination, PADs can also act as
direct coactivators of speciﬁc transcription factors to induce
other histone modiﬁcations that aﬀect gene expression. As such,
it was shown that PAD4 associates with several transcriptionally
active promoters and functions as an activator of c-Fos via a
mechanism that involves facilitated phosphorylation of the
ETS-domain protein Elk-1.74 EGF-induced activation of PAD4
results in the direct targeting of Elk-1 for citrullination, thereby
increasing ERK-mediated-phosphorylation-induced activation
of Elk-1. Activated Elk-1 exhibits enhanced association with the
histone acetyltransferase p300, which ultimately induces
histone H4K5 acetylation and concomitant increased gene
transcription.
In addition to the citrullination of histones and transcription
factors, the PADs citrullinate a number of other proteins,
including themselves. For example, PAD4 is known to
autocitrullinate at numerous sites in vitro and in vivo.30b,75
There have been some conﬂicting observations regarding the
functional impact of PAD4 autocitrullination. One report
claimed that autocitrullination reduces PAD4 activity.75 By
contrast, another study did not detect any signiﬁcant inﬂuence
on catalytic activity.30b In addition, it was shown that PAD4
autocitrullination alters protein−protein interactions and is
thought to weaken the interaction between PAD4 and
citrullinated H3 as well as PRMT1 and the histone deacetylase
HDAC1.30b Autocitrullination of PAD4 was also proposed to
destabilize a corepressor complex consisting of PAD4 and
HDAC1, thereby providing a potential mechanism for
decreasing the corepressor activity of this complex.30b
2.6.3. Nonepigenetic Eﬀects of Histone Citrullination.
It was postulated that PAD4-mediated citrullination at H4R3
may represent an “apoptotic histone code” to detect damaged
cells and induce nuclear fragmentation.76 DNA damage induces
PAD4 expression and the concomitant citrullination of various
proteins.77 In this respect, PAD4 was shown to citrullinate H4
at arginine 3 and that this activity was blocked by small
interfering RNAs (siRNAs) against p53 or PAD4.76 In addition,
the presence of H4R3 Cit correlates with the level of apoptosis
induction in DNA-damage-exposed U2OS cells. Citrullination
of H4R3 was proposed to enhance accessibility of nucleosomal
DNA, thereby promoting its apoptotic fragmentation.76
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Moreover, PAD4 was shown to citrullinate the nuclear lamina
protein lamin C, suggesting the involvement of lamin C
citrullination in nuclear fragmentation during apoptosis.76
Histone citrullination is also implicated in innate immunity,
where PAD4-mediated histone citrullination is involved in the
formation of NETs (Figure 20).78 NETs, which were ﬁrst
identiﬁed in 2004 by the Zychlinsky group, are composed of
nuclear DNA and associated proteins that are ejected by
neutrophils in response to an infection.79 Although the
physiological function of NET formation is incompletely
understood, NETs are thought to function as a pro-
inﬂammatory form of cell death, known as NETosis, that
links the innate and adaptive immune responses. Speciﬁcally,
NETs are formed in response to a number of stimuli of both
bacterial and human host origin that trigger the release of
chromatin to form a weblike structure that can trap pathogens
and prevent them from spreading throughout the body.
NETs also increase the local concentration of coextruded
antimicrobial agents, including histones, myeloperoxidase
(MPO), and proteases. Notably, several decades earlier, it
had already been shown that histones, in particular H3 and H4,
possess bactericidal activity,80 thereby providing at least a
partial explanation for the release of histones during NETosis.
NET-forming stimuli include lipopolysaccharide (LPS), N-
formyl-methionine-leucine-phenylalanine (f-MLP), lipoteichoic
acid (LTA), tumor necrosis factor (TNF), interleukin-8 (IL-8),
and hydrogen peroxide.78b,d Although the speciﬁc cellular
pathways that trigger NET formation are an area of intense
investigation, they are currently incompletely understood.
Nonetheless, there appears to be a requirement for the
generation of reactive oxygen species (ROS), since neutrophils
from patients with chronic granulomatous disease, which is due
to mutations in the ROS-generating enzyme nicotinamide
adenine dinucleotide phosphate (NADPH) oxidase, do not
form NETs. In addition, PAD4 activity is a prerequisite and
likely the terminal point in this signal transduction cascade
because genetic deletion or chemical inhibition of PAD4 results
in mouse neutrophils that are unable to citrullinate histones and
do not form NETs.78a,c,81 Thus, PAD4 is a crucial component
of the innate immune system in mammals.
2.7. Histone Citrullination in Disease
Dysregulated PAD expression and aberrant protein citrullina-
tion have been implicated in numerous human diseases as
summarized in several excellent reviews.13,82 Here, we focus on
diseases where a direct link between histone citrullination and
disease has been established by discussing the involvement of
histone citrullination in cancer and inﬂammatory diseases.
2.7.1. Histone Citrullination in Cancer. Histone
modiﬁcations play an important role in tumor development
and cancer.83 In this respect, PAD4 is overexpressed in various
malignant tumor tissues, including osteosarcoma, several
adenocarcinomas aﬀecting the colon, esophagus, ovaries,
pancreas, and stomach, and carcinomas of the breast, bladder,
endometrium, and liver, suggesting that it might be involved in
tumors derived from multiple tissue origins.84 It was proposed
that aberrant histone modiﬁcations can induce tumor
suppressor gene silencing, thereby promoting tumorigenesis.83b
A key regulator of cell cycle arrest, and programmed cell death,
is the tumor suppressor p53, which is mutated in about half of
cancers and thereby represents the most frequently altered gene
in human cancers.85 p53 is a DNA-binding protein that is
responsible for the integration of diverse signals, such as
starvation, DNA damage, and various stress signals, by
regulating numerous downstream genes that help to cope
with stress and control cell fate. As described above, PAD4
functions as a corepressor of p53 to repress its downstream
tumor suppressor genes such as p21, GADD45, and PUMA.65,66
Notably, both PAD4 knockdown and inhibition with Cl-
amidine result in increased expression of these p53 target genes
and increased cell death.65,66 In addition, in osteosarcoma
U2OS cancer cells, PAD4 represses the expression of the p53
target gene SESN2, which encodes an upstream inhibitor of the
mammalian target of the rapamycin complex 1 (mTORC1)
signaling pathway to regulate cellular autophagy.57 Consis-
tently, the PAD inhibitor YW3-56 (14) induces autophagy in
U2OS cells.57 In summary, PAD4 might induce tumorigenesis
through multiple mechanisms, including chromatin deconden-
sation resulting in a stem-cell-like state, inhibition of tumor
suppressor genes by corepressing p53 target genes, and
inhibition of autophagy and the concomitant increase in
protein synthesis and cell growth.
Figure 20. NET formation in neutrophils.
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Interestingly, Tanikawa and colleagues observed that the
expression of PAD4 is activated by p53, which binds to the p53-
response element p53BS-A in intron 1 of the PAD4 gene.
These data indicate that PAD4 may form part of a negative
feedback loop to regulate p53 activity.76,77 These data further
imply that aberrant histone citrullination caused by dysregu-
lated PAD enzyme activity is actively involved in cancer
progression. Given the close link between PADs and cancer,
PAD4 represents a suitable target for cancer drug development.
In this respect, the PAD inhibitors Cl- and F-amidine both
exhibit cytotoxic eﬀects toward several cancerous cell lines such
as HL-60, MCF7, and HT-2, whereas no eﬀect was observed in
noncancerous lines such as NIH 3T3 and HL-60 granulo-
cytes.86 In addition, these PAD inactivators also potentiate the
cytotoxicity of the commonly used anticancer drug doxor-
ubicin.86 Moreover, the Coonrod group showed that the level
and activity of PAD2 increase during the transition of normal
mammary epithelium to fully malignant breast carcinomas and
coincides with HER2/ERBB2 upregulation.87 In addition, when
treating MCF10DCIS monolayer carcinoma cells with Cl-
amidine, they observed a strong suppression of cell growth in
culture, which is induced by cell cycle arrest in the S-phase,
followed by apoptosis. Moreover, administration of Cl-amidine
to mice containing MCF10DCIS-injected tumor xenografts, a
preclinical model of breast cancer, suppresses tumor growth.87
Although high-level PAD expression and histone citrullina-
tion are generally considered to be characteristic features of
cancer cell proliferation, recently, however, the Coonrod group
identiﬁed a strong correlation between high PAD2 expression
and H3R26 Cit with increased survival in estrogen receptor
positive (ER+) tumor patients.73 The authors further suggest
that histone citrullination might be a critical prognostic for ER+
tumor development and is thus suited to stratify ER+ tumors
into clinically relevant subsets. This observation also raises the
intriguing question of whether histone citrullination may act as
either a tumor promoter or a suppressor mark in a context and
or isozyme-dependent manner. Therefore, further studies are
necessary to clarify the detailed roles of individual PADs during
tumor development and to understand whether they function
as tumor suppressors or oncogenes.
2.7.2. Histone Citrullination in Inﬂammatory Diseases.
Altered histone citrullination is also observed in a range of
inﬂammatory diseases such as RA, lupus, ulcerative colitis,
Alzheimer’s disease, and multiple sclerosis.82d Despite their
great diversity, a common molecular feature of at least a subset
of these diseases is aberrantly upregulated NET formation due
to the presence of activated immune cells. As such, progression
of these inﬂammatory diseases may result from the
inappropriate and exaggerated induction of NET formation.
For example, neutrophils obtained from RA patients are more
likely than control neutrophils to spontaneously release
NETs.78e Lupus neutrophils possess a similar phenotype, and
it is notable that hallmarks of RA and lupus include
autoantibodies that bind speciﬁcally to citrullinated proteins
(RA) and double-stranded DNA (lupus), which are both
released from neutrophils during NETosis. Consistent with a
role for PAD4 in this process is the fact that both Cl-amidine
and GSK199 inhibit NET formation.50,58 Additionally,
neutrophils isolated from PAD4(−/−) mice cannot form
NETs after stimulation with chemokines or incubation with
bacteria, highlighting that the PAD4 function is critical in
diseases associated with aberrant NET formation.78c With
respect to RA, the links between dysregulated PAD4 activity
and disease onset are extremely strong because, in addition to
its important role in NET formation, a genome-wide haplotype
study identiﬁed four single-nucleotide polymorphisms (SNPs)
in PAD4 that are associated with an increased risk of
developing RA.88 Additionally, the most speciﬁc diagnostic
for RA is the presence of antibodies to citrullinated proteins,
the product of the PAD reaction, and these antibodies now
form part of the clinical diagnostic criteria.89 Furthermore,
these autoantibodies are present before clinical disease and are
predictive of a more severe and erosive form of the disease.90
Notably, it was demonstrated that treatment of mice
suﬀering from collagen-induced arthritis (CIA) with Cl-amidine
reduces disease severity, joint inﬂammation, and joint damage
in a dose-dependent manner without apparent signs of
cytotoxic eﬀects.91 Moreover, Cl-amidine was also eﬀective in
a mouse model of ulcerative colitis where its oral or
intraperitoneal administration increased the colon length, as
well as mouse mobility and activity, and reduced the disease
severity.92 Recently it was shown that PAD inhibition using BB-
Cl-amidine and Cl-amidine mitigates vascular, kidney, and skin
disease in an MRL/lpr mouse model of lupus.58 Speciﬁcally,
these PAD inhibitors not only reduce NET formation and
interferon (IFN) production, which has been associated with
the development of endothelial dysfunction in lupus,93 but also
decrease immune complex deposition in kidneys and reduce
proteinuria, which constitute major characteristics of this
disease. Taken together, inhibition of NET formation by
PAD-speciﬁc inhibitors represents a promising therapeutic
strategy to combat diﬀerent inﬂammatory diseases.
Since aberrant NET formation including concomitant
increased levels of citrullinated histones is also present in
deep vein thrombosis and myocardial infarct formation,
inhibition of PAD4 activity also represents a suitable target to
interfere with these serious cardiovascular diseases.94 Indeed,
recent data with both Cl-amidine and BB-Cl-amidine support
this hypothesis.58,81 Apart from PAD-mediated citrullination of
histone proteins and NET formation, PAD4 and PAD2 were
also shown to hypercitrullinate myelin basic protein (MBP),
resulting in the demyelination of the myelin sheath and
aﬀecting nerve cell signal transduction, thereby promoting the
development of multiple sclerosis (MS).95 In this respect, the
PAD inhibitor 2-chloroacetamidine has shown eﬃcacy in
multiple preclinical models of MS, indicating that PAD
enzymes may also represent a therapeutic target for MS.96
2.8. Future Areas of Protein Citrullination Research
Although most studies dealing with histone citrullination focus
on its nuclear eﬀects regarding the modulation of gene
expression, it is evident that protein citrullination, even on
histone proteins, also exists in the extracellular environment of
human sera. The presence of hypercitrullinated proteins,
including histones, is a well-documented highly speciﬁc marker
for rheumatoid arthritis that has diagnostic and prognostic
value as well as potential therapeutic implications.97 Since PAD
inhibitors can block the accumulation of these hypercitrulli-
nated (histone) proteins and the incidence of anticitrulline
antibodies as well as aberrant NET formation, inhibition of
PAD function represents a promising target to treat a number
of diﬀerent inﬂammatory diseases which are linked to
hypercitrullination and abnormal NET formation.
Regarding the function of protein citrullination in epigenetic
regulation, it will be of great interest to screen for enzymes that
can reverse protein citrullination as well as to identify potential
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citrullination reader proteins that may recognize and integrate
this emerging epigenetic mark into the cellular interpretation of
the histone code. Since PADs are calcium-dependent enzymes
that require near millimolar concentrations of calcium to
eﬃciently citrullinate its protein substrates in vitro, it also
remains a topic of future research to elucidate how the PADs
get activated in vivo, as cellular calcium concentrations typically
remain at low micromolar levels. Another critical aspect to
further advance the current knowledge of PAD biology is the
generation of isozyme-selective inhibitors to ascertain the
physiological contribution of the individual enzymes in health
and diseases. In addition, the development of next-generation
PAD inhibitors with enhanced selectivity, bioavailability, and
pharmacokinetic stability as well as preferentially reversible
inhibitors to minimize potential oﬀ-target eﬀects encountered
by irreversible inhibitors is highly desirable.
3. HISTONE ARGININE METHYLATION
3.1. Overview of Protein Arginine Methylation
Protein arginine methylation is a common post-translational
modiﬁcation that regulates numerous cellular processes,
including gene transcription, mRNA splicing, DNA repair,
protein cellular localization, cell fate determination, and
signaling.98 Notably, it was shown that about 2% of the total
arginine residues isolated from rat liver nuclei are dimethy-
lated.99 The formation of this PTM is catalyzed by the PRMT
family of methyltransferases. Currently, there are nine PRMTs
annotated in the human genome (Figure 21).100 In addition,
two distantly related proteins, FBXO10 and FBXO11, show a
low degree of sequence homology to some PRMT motifs, but
lack the important substrate-binding double E-loop and THW
loop.101 Although the human ﬂag-tagged FBXO11 protein was
proposed to harbor arginine methyltransferase activity, the
human HA-tagged version of the protein and the Caeno-
Figure 21. Schematic depiction of the human PRMT family. The SAM-binding methyltransferase region is highlighted in olive green. All family
members contain the methyltransferase signature motifs I, post-I, II, and III and the conserved THW loop, labeled as red bars, respectively. Sequence
motifs with low or no sequence similarity are depicted in light red. Abbreviations: SH3, SH3 domain; Zn, zinc ﬁnger motif; TPR, tetratricopeptide
repeat.
Figure 22. PRMTs are SAM-dependent enzymes that catalyze the transfer of methyl groups onto peptidyl arginine residues. There are three types of
PRMTs that are classiﬁed according to the site of modiﬁcation. Type I enzymes generate asymmetric dimethylations, type II enzymes form
symmetric dimethylations, and the type III enzyme PRMT7 only catalyzes monomethylation reactions.
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rhabditis elegans FBXO11 orthologue DRE-1 did not show any
methyltransferase activity in a subsequent study.101a,102 There-
fore, FBXO10 and FBXO11 are not considered as true
PRMTs.103 Notably, chemogenetic analyses suggest that there
may be as many as 44 PRMTs in the human proteome.101c
Whether all of these enzymes represent bona ﬁde PRMTs has
yet to be proven deﬁnitively.
The nine S-adenosyl-L-methionine (SAM or AdoMet)-
dependent enzymes can be further classiﬁed into three types
according to their preferred methylation products as the
terminal amine(s) of the arginine guanidinium group may be
monomethylated or symmetrically or asymmetrically dimethy-
lated to form monomethylarginine (MMA), symmetric
dimethylarginine (SDMA), and asymmetric dimethylarginine
(ADMA), respectively (Figure 22). Therefore, PRMT-medi-
ated arginine modiﬁcations add either ∼14 Da (MMA) or ∼28
Da (SDMA or ADMA) to the overall mass of the histone
protein. However, as can be seen in Figure 23A, methylation
does not perturb the overall positive charge of the arginine
guanidinium group, but changes potential hydrogen bond
interactions, since the number of added methyl groups reduces
the hydrogen bond donor sites accordingly. On the basis of
experimental studies performed with guanidine and a diverse
series of methylated guanidine derivatives, the pKa of guanidine
is 13.6, whereas the pKa values for N-methylguanidine and N,N-
dimethylguanidine are 13.4.104 Interestingly, the pKa value for
the N,N′-dimethylguanidine is 13.6, indicating that mono-
methylated and asymmetrically dimethylated guanidines are
only slightly weaker bases than symmetrically dimethylated
guanidines. Thus, the major eﬀects of this modiﬁcation are
steric eﬀects as well as changes in hydrogen bond interactions
as opposed to the electronic eﬀects observed with citrullination.
Moreover, the addition of methyl groups alters the shape of
the arginine side chain. Due to the electron delocalization in the
arginine guanidinium group and possible rotations around the
central carbon−nitrogen bonds, distinct stereoisomers can
occur in MMA and SDMA (Figure 23B). On the basis of
density functional theory (DFT) calculations, the anti−syn
conformation was shown to be the most favorable SDMA form,
highlighted by a diﬀerence in the ground-state energies for the
anti−anti and anti−syn SDMA conformations of 2.8 kcal
mol−1.105 A plausible reason for this diﬀerence may be steric
eﬀects that would disfavor the close proximity between both
methyl groups in the anti−anti conformation. However, the
activation energy for rotation around the bond between the
central guanidinium carbon, Cζ, and one of the terminal
nitrogens, Nω, is 14 kcal mol
−1, indicating that conversion of
the diﬀerent conformations can occur at room temper-
ature.105,106 In addition, the diﬀerent stereoisomers represent
diﬀerent hydrogen-bonding patterns that might be harnessed
for speciﬁc protein interactions. For instance, the anti−anti
SDMA conformation was shown to be preferentially bound to
the Tudor domains of the human SMN and SPF30 proteins,
whereas the extended Tudor domains of the Drosophila
TUDOR protein and the human SND1 were shown to bind
SDMA in the anti−syn conformation.105,107
Most PRMTs generate ADMA and are classiﬁed as type I
enzymes (PRMT1−4, PRMT6, PRMT8), with PRMT1
accounting for >50% of the normal steady-state levels of
ADMA.108 Of the remaining enzymes, PRMT5 and PRMT9
are the only known type II enzymes that catalyze the formation
of SDMA, whereas PRMT7 is a type III enzyme that can only
generate MMA on its substrates (Figure 22).109 In addition to
these human PRMT orthologues, yeast encodes a PRMT that
catalyzes the monomethylation of the internal (Nε) guanidi-
nium nitrogen atom.110 Given the unique speciﬁcity of this
enzyme, it has been classiﬁed as a type IV enzyme. Notably,
however, sequence analyses indicate that there is no homologue
of this type IV enzyme in higher eukaryotic organisms.
3.2. Structure−Mechanism of PRMTs
All PRMTs contain a conserved catalytic core region of
approximately 310 amino acids, and several PRMTs possess
additional domains (e.g., SH3, Zn ﬁnger, TIM barrel, and TPR)
that have been suggested to diversify the substrate speciﬁcity of
the enzymes and to regulate their activity (Figure 21).98d
Typically, PRMTs possess a single catalytic core region.
PRMT7 and PRMT9, however, harbor two consecutive
methyltransferase domains that may have arisen by gene
duplication.111 The catalytic core region comprises ﬁve highly
characteristic signature motifs (Figures 19 and 22), including
Figure 23. (A) Electrostatic surface potential and hydrogen-bonding
donor sites of the side chain of arginine, and the methylated arginine
side chains of MMA, ADMA, and SDMA. Cα denotes the α-carbon.
Charge potentials were rendered by using SPARTAN (Wavefunction
Inc.), with negative electrostatic charges shown in red, positive charges
in blue, and neutral charges in green. (B) Distinct stereoisomers for
MMA and SDMA. Methyl groups are highlighted in yellow, whereas
hydrogen-bonding donor sites are marked in red. Stereoisomers
emerging from rotation around the central Cζ−Nε bond are omitted
for simplicity.
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(i) motif I (VLD/EVGXGXG), which forms the base of the
SAM-binding site and is structurally homologous to sequences
found in other nucleotide-binding proteins, (ii) post I (L/V/
IXG/AXD/E), which is important for hydrogen bond
formation to each hydroxyl of the ribose part of SAM via the
carboxylate of the acidic residue, (iii) motif II (F/I/VDI/L/K),
which stabilizes motif I by the formation of a parallel β-sheet,
(iv) motif III (LR/KXXG), which forms a parallel β-sheet with
motif II, and (v) the THW loop, which is close to the active site
cavity and helps stabilize the N-terminal helix, which is
important for substrate recognition.100
3.2.1. Structure of PRMTs. The crystal structures of
several PRMTs revealed that these proteins mainly exist as
homodimeric head-to-tail protein complexes (Figure 25A).112
It was proposed that the dimer is critical for proper substrate
binding and therefore is required for activity.112c By contrast,
PRMT7, the only known type III methyltransferase, is unusual
in that it contains two PRMT core units arranged in tandem
(Figure 21). Gel ﬁltration proﬁles and small-angle X-ray
scattering (SAXS) experiments indicated that the PRMT7
orthologue from C. elegans exists as a monomer in solution,
even in the presence of SAM.113 Notably, the recent crystal
structures of mouse and C. elegans PRMT7 revealed that the
second methyltransferase domain folds back onto the ﬁrst
catalytically active domain, and thereby forms a pseudodimeric
form of the enzyme (Figure 26).113,114
In mouse PRMT7, the two PRMT modules are bridged by a
19-residue linker. Overall, the general architecture is very
similar to that of other known PRMT dimer structures.
However, only the ﬁrst (N-terminal) module is active, since the
second PRMT module contains several mutations that impair
SAM cofactor binding and does not contain a proper double E-
loop, thereby rendering this module catalytically nonproduc-
tive.114 Moreover, the crystal structures revealed a tight
interaction between both modules, which are further stabilized
by a zinc ﬁnger.114 Interestingly, the interface between both
PRMT modules does not contain the typical hole observed in
the other PRMT dimer structures and might therefore restrict
the ﬂexibility and orientation of peptidyl substrates (Figure
26).114 Notably, PRMT7 derived from plants and Trypanosama
are composed of a single PRMT module. Wang et al., however,
observed that PRMT7 derived from Trypanosoma brucei exists
Figure 24. Sequence alignment of the SAM-binding methyltransferase region of human PRMT family members. The product speciﬁcity-determining
residue is highlighted with a blue asterisk below the alignment. Catalytic residues located on the double E-loop are highlighted with red asterisks
below the alignment. The sequence alignment was generated using Clustal Omega and visualized using Espript 3.0.229 The relative accessibility of
each residue is depicted below the consensus motif: blue indicates accessible residues, cyan marks intermediately accessible residues, white stands for
buried residues, and red indicates that the accessibility is not predicted.
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as a dimer on the basis of SAXS analysis, and also the available
crystal structure of T. brucei PRMT7 (TbPRMT7) conﬁrms its
dimeric organization (Figure 26).115 Although TbPRMT7 is
active as a homodimer, it strictly generates monomethylated
arginine residues, indicating that the presence of tandemly
arranged PRMT modules versus two active PRMT modules in
trans orientation are not critical for determining product
speciﬁcity.114,115
On the basis of the available crystal structures, the catalytic
core region consists of three structurally and functionally
distinguishable regions as exempliﬁed by the structure of
PRMT1 (Figure 25A). The most critical is the SAM-binding
domain, which is highly conserved in other SAM-dependent
methyltransferases.116 This SAM-binding domain adopts a
typical Rossmann fold and is followed by the β-barrel domain,
which is quite unique to the PRMT family and is thought to be
important for substrate binding.117 Moreover, the β-barrel
domain contains an α-helical insertion that acts as a
dimerization arm. Despite the variation in amino acid
sequences (Figure 24), the crystal structures of several
PRMTs reveal highly similar general folds. In addition, key
structural features such as the active site double E-loop, which
is critical for guanidinium binding, as well as the SAM-binding
residues and several β-strand-forming signature motifs, are
conserved among all PRMTs.
Within the active site are a number of conserved residues
that are important for SAM binding, catalysis, and maintaining
the overall architecture of the PRMT1 active site (Figure
27).112c These residues include E129 and V128, which are both
located on a loop preceding motif II and directly interact with
the SAM adenine ring and E100, which forms a bidentate
hydrogen bond to the ribose moiety. The side chain of H45
projecting from an N-terminal helix, denoted αY, also hydrogen
bonds to a ribose hydroxyl group. Moreover, proper positioning
of the SAM cofactor is further mediated by the side chain of
M155. The methionine portion of SAM is bound to the side
chains of D76, recognizing the free α-amine, whereas R54
forms a bidentate interaction with the carboxylate group. R54
also hydrogen bonds with the side chain of E144 to orient the
γ-carboxylate of this residue for optimal electrostatic and
hydrogen bond interactions with the ω-nitrogen atom of a
substrate arginine. E144 is part of the substrate-binding double
E-loop, which also harbors E153. The side chain carboxylates of
both of these residues are thought to recognize and align the
arginine guanidinium substrate for proper catalysis to occur.
Notably, in the structure of PRMT1, the position of this residue
does not appear to be catalytically competent since the
orientation of the E153 side chain is out of the active site.112c
3.2.2. PRMT Substrate Recognition. On the basis of
sequence motif analysis, there are no conserved residues
surrounding the sites of arginine methylation.118 The only
exception is glycine, which is slightly enriched, especially at
positions +1 and +2 following the arginine substrate. However,
arginine methylation is often found in unstructured protein
regions, including loops, as well as N- or C-terminal regions.119
The lack of structured segments can be rationalized by the deep
active site cavity of the PRMTs, which only allows arginine
residues present on kinked loops to enter. This structural
restraint was highlighted by the peptide-bound PRMT5·MEP50
complex, which revealed the presence of a characteristic β-turn
in the peptide substrate (Figure 28).120
Speciﬁcally, the substrate arginine is located at the tip of the
β-turn, which is stabilized by a hydrogen bond between the
main chain carbonyl oxygen of S1 and the backbone amide
nitrogen of G4. In addition, the carbonyl oxygen and the amide
nitrogen of S1 form a bidentate hydrogen bond to the Q309
amide side chain group of PRMT5. Similar to the PAD4−
substrate peptide interaction, the majority of the interactions
between the substrate peptide and PRMT5 are mediated by
peptide backbone interactions, rationalizing the lack of strict
sequence speciﬁcity. The only exception represents a direct
hydrogen bond between the side chain of K5 and the carbonyl
oxygen of PRMT5 P311. Interestingly, PRMT5 also utilizes
several backbone hydrogen bond interactions originating from
the main chain of S310, P311, L312, and F580. This
observation may explain the lack of sequence conservation of
these residues among diﬀerent PRMT members. Moreover, the
hydroxyl group of Y307 hydrogen bonds to the backbone
carbonyl oxygen and amide nitrogen of substrate residues G6
Figure 25. (A) PRMT1 exists as a head-to-tail dimeric protein that
comprises four characteristic functional regions, as indicated (PDB
code 1OR8). (B) Surface representation of dimeric PRMT1 colored
according to its electrostatic surface potential. The catalytic sites of
both protomers are located on the same dimer side and are facing each
other, separated by ∼30 Å.
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and K8, respectively. Thus, the fact that glycine-rich sequences
are preferentially targeted is consistent with their ability to
endow the polypeptide chain with enhanced conformational
freedom, which would facilitate the formation of such β-turn
structures. Thus, the context in which an arginine is placed is
important for substrate recognition. Moreover, the preference
for peptide stretches that can adopt β-turn-like structures
coincides with the substrate speciﬁcity of PADs, implying that
PRMTs and PADs might compete for similar substrates. This
appears to be the case because, as noted above, in several
instances the methylation and citrullination status of speciﬁc
arginines in histones are inversely correlated and possess
distinct and opposing eﬀects on transcription (see section
2.6.1).
In addition to these structural constraints, local sequences
next to the modiﬁed arginine are also important for substrate
recognition by some PRMTs. As mentioned above, PRMTs,
such as PRMT1, PRMT3, PRMT5, PRMT6, and PRMT8,
typically target glycine-rich sequences.98d,121 Contrarily,
PRMT4 prefers to methylate arginines embedded within
proline-, glycine-, and methionine-rich motifs.122 Moreover,
crosstalk with lysine acetylation was shown to be critical to
enhance H3 peptide substrate methylation by PRMT4 at
H3R17, as kinetic studies revealed that PRMT4 has a 5-fold
higher activity toward an H3K18-acetylated peptide than the
unmodiﬁed peptide.112d
Interestingly, the only type III enzyme, PRMT7, speciﬁcally
recognizes arginines within an RXR motif present in H2B and
H4 (see section 3.6).123 There, it was shown that PRMT7
preferentially modiﬁes the N-terminal arginine of the RXR
motif (i.e., H2BR29, H2BR31, and H4R17). Notably, eﬃcient
catalysis depends on the presence of the second arginine since
the replacement of the second arginine by lysine leads to a
signiﬁcant reduction in the methylation signal.123 Although the
cocrystal structure of TbPRMT7 bound to a 21-residue histone
H4 peptide was recently solved, only the ﬁrst four residues
(SGRG) of this peptide could be observed.115 This structure
revealed that the peptide substrate forms a wide turn on the
surface of the active site, but not a characteristic β-turn (Figure
29). The side chain guanidinium of the arginine substrate forms
ﬁve hydrogen bonds to both double E-loop glutamate residues
(E172 and E181) and glutamine Q329, which occupies the
same position as the central histidine in the THW loop.
Mutagenesis studies further revealed that the glutamine residue
Q329 can be substituted by a histidine without loss of
activity.115 Similar to that in PRMT5, the peptide substrate in
PRMT7 is also recognized by several hydrogen bond
interactions with the substrate amide backbone. Speciﬁcally,
the carboxylate of D70, originating from helix αY, makes
hydrogen bonds with the main chain amides of residues S1 and
G2, and T176, situated on the double E-loop, hydrogen bonds
to the backbone carbonyl and the amide of the substrate
residue R3. These data indicate that main chain interactions are
critical for substrate binding, and the lack of a β-turn in the
peptide substrate indicates that PRMT7 may accommodate a
wider range of peptide sequences apart from glycine-rich
elements.
For most PRMTs, substrate recognition relies to a great
extent on remote sequences (>14 residues distant from the
arginine).124 This stands in contrast to the PADs, where long-
range interactions are unimportant.19 These distal elements are
typically positively charged and are thought to interact via ionic
interactions with several negatively charged patches found on
PRMT1 (Figure 25B).112c In this respect, mutation of acidic
residues in PRMT1 leads to compromised enzyme activity or
altered methyltransferase substrate speciﬁcity.125 Notably,
eﬃcient PRMT-mediated methylation reactions require long
peptide substrates, i.e., 21 residues of the N-terminal tail of
histone H4 (acH4-21), to achieve H4R3 methylation kinetics
comparable to that of full-length H4.124b N-terminal truncation
of the two residues preceding the methylated arginine residue
(H4−21Δ(1−2)) decreased the methylation eﬃciency by
∼104-fold, thereby indicating that interactions between the
enzyme and the backbone amide N-terminal to the site of
methylation are critical for substrate recognition as conﬁrmed
by structural analysis. A similar approach employing C-terminal
truncation peptides revealed that removal of three residues
(AcH4-18) decreased arginine methylation by 150-fold in
human PRMT1, while further truncation by three additional
residues (AcH4-15) further diminished activity by 860-fold.124b
These data clearly indicate that remote sequences are critical for
eﬃcient substrate capture, by mediating strong charge−charge
interactions between the acidic patches in the SAM-binding
domain as well as the β-barrel domain of PRMT1 (as described
above) and positively charged residues such as K16, R17, R19,
and K20 in the distal portion of the H4 tails.112c,124b,125 Since
Figure 26. Homodimeric PRMT1 contains two active sites and a
central hole (PDB code 1OR8). Monomeric PRMT7 from Mus
musculus harbors only one active site and does not possess a central
hole (PDB code 4C4A). Homodimeric PRMT7 from T. brucei
contains two active sites and does not possess a central hole (PDB
code 4M37).
Figure 27. Active site architecture of PRMT1 bound to arginine (PDB
code 1OR8). The structural elements are color coded according to
Figure 25. The image on the right depicts details of the PRMT1 active
site, highlighting critical residues for substrate binding and catalysis.
Polar contacts of <3.5 Å are represented as dashed lines.
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the great majority of PRMTs form dimers, it is conceivable that
this increased amount of distal substrate-binding sites,
represented by acidic patches in PRMT1, facilitates the
processive dimethylation of Arg residues by allowing the
product of the ﬁrst methylation reaction, monomethylarginine,
to enter the active site of the second molecule of the dimer
without releasing the substrate from the homodimer. This
model is further supported by the high aﬃnity, also reﬂected by
a low KM value, between substrates and the PRMT dimer and
the loss of activity of engineered PRMT monomers.112b,c
Osborne and colleagues further revealed that PRMT1
employs a partially or semiprocessive mechanism, indicating
that the substrate stays bound to the enzyme for two
consecutive methylation reactions, and the major substrate
released is ADMA.124b Similar results have been obtained for
PRMT6 as this enzyme has also been suggested to show some
processivity.126 By performing double-turnover reaction experi-
Figure 28. PRMT5·MEP50 (pink) complex bound to histone H4 peptide (gray) (PDB code 4GQB). Polar contacts of <3.5 Å are represented as
dashed lines. The highly conserved active site glutamate residues Glu435 and Glu444, forming the double E-loop, bind to the substrate guanidinium
group. The hydrogen bond (highlighted in yellow dashed lines) between the carbonyl oxygen of S1 and the amide nitrogen of G4 stabilizes the β-
turn conformation. Abbreviation: ac, N-terminal acetylation.
Figure 29. PRMT7 (purple) from T. brucei bound to histone H4 peptide (gray) (PDB code 4M38). Polar contacts of <3.5 Å are represented as
dashed lines.
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ments, the Hevel group observed both MMA and ADMA
formation, conﬁrming a general semiprocessive mechanism of
PRMT1 catalysis.127 Interestingly, the proportions of MMA
and ADMA generated are diﬀerent among distinct peptide
substrates. For example, the N-terminal H4 peptide SGRGK-
GGKGLGKGGAKR is preferentially processed through a
processive mechanism, leading to a dimethylated product,
while other sequences such as the ﬁbrillarin-based RKK peptide
GGRGGFGGKGGFGGKW partition more frequently through
a distributive mechanism where both monomethylated and
dimethylated products are ultimately generated. These
observations clearly indicate that the degree of processivity is
controlled in a substrate-dependent manner and thus distinct
patterns of methylation can be deposited by the same PRMT
enzyme.127 Thus, conﬂicting observations regarding the
processive or distributive nature of PRMT1 activity may be
partially due to the diﬀerent substrates used and hence changes
in the substrate-induced processivity rate. By contrast, recent
data indicate that PRMT5 uses a distributive mechanism to
catalyze the symmetric dimethylation of histone H4 and its N-
terminal peptide fragment.120,124c,128
3.2.3. PRMT Product Selectivity. Structural comparison
of several PRMTs reveals similar active site architectures,
thereby suggesting that these enzymes employ a similar
catalytic mechanism to eﬀect substrate methylation (Figure
30).112a,c,e,114 Interestingly, the catalytic domain of PRMT5,
which catalyzes SDMA formation, is also highly similar to that
of the ADMA-generating type I enzymes as judged by the very
high degree of consersation between the available crystal
structures (Figure 31).120,129 However, the molecular basis for
their distinct product formation paths is largely unknown.
Recent reports proposed that a conserved phenylalanine
(F327) in the active site of PRMT5 is important for directing
symmetric dimethylation, while a methionine (M48) residue in
PRMT1 confers speciﬁcity toward asymmetric dimethyla-
tion.129,130 These observations imply that the generation of
symmetrically and asymmetrically dimethylated arginine
residues share a common catalytic mechanism, as type I and
type II mutant enzymes are capable of performing both of these
reactions. Notably, on the basis of the PRMT5 structure, F327,
which has been shown to be important for specifying the
symmetric dimethylating activity of PRMT5, interacts with the
substrate guanidinium group, thereby orienting it for methyl
transfer (Figure 31).120 Quantum mechanical models further
revealed that the free energy of activation, ΔG⧧, for SDMA
formation is 13.4 kcal/mol, and therefore, SDMA formation is
more energetically costly than ADMA formation, for which a
ΔG⧧ of 10.2 kcal/mol was calculated.130 The higher energy
barrier for forming SDMA over ADMA presumably explains the
low amount of SDMA formed by a PRMT1M48F mutant and
is also reﬂected by the 160-fold slower rate for symmetric
dimethylation, using monomethylated arginine as the substrate,
compared to the monomethylation rate observed with
PRMT5.131 By contrast, the PRMT1-catalyzed rate of
dimethylation is only 2−4-fold slower than the rate of the
monomethylation reaction.124b Moreover, introduction of an
F379M substitution into PRMT5 partially shifts the product
formation speciﬁcity such that this enzyme can now generate
ADMA, albeit with reduced eﬃciency compared to that of
PRMT1.129 However, it still remains to be determined what
other structural features, apart from the mentioned phenyl-
alanine to methionine switch, contribute to product speciﬁcity,
especially since PRMT9, the other type II enzyme, does not
contain a phenylalanine but a methionine at this position. As
such, it was recently proposed that subtle diﬀerences in the size
of the arginine-binding pocket, mainly due to alterations of the
THW loop, may be important for controlling the product
selectivity of the PRMTs.113,114 In this respect, it is interesting
to note that all PRMTs, except the type II enzymes PRMT5
and PRMT9, contain a histidine in the THW loop. PRMT5 and
PRMT9 possess serine and cysteine residues at the
corresponding site, respectively. It is tempting to speculate
that the bulky side chain of histidine impairs binding of MMA,
whereas the much smaller side chains of serine and cysteine
allow for proper accommodation of a symmetrically dimethy-
lated guanidinium group in the active site pocket (Figure 32).
3.2.4. Proposed Catalytic Mechanism of PRMTs.
PRMTs employ a bisubstrate mechanism, transferring the
methyl group of SAM to speciﬁc arginine residues in histone
and nonhistone protein substrates, resulting in mono- and
dimethylated arginine residues and the byproduct S-adenosyl-L-
homocysteine (SAH or AdoHcy). According to the enzyme
classiﬁcation nomenclature, PRMTs belong to the class of
transferases that transfer one-carbon groups (EC 2.1.1.125).
Figure 30. Structural representation of the active site of rat PRMT1
(PDB code 1OR8), rat PRMT3 (PDB code 1F3L), rat PRMT4 (PDB
code 3B3F), and mouse PRMT7 (PDB code 4C4A). All structures
contain a bound cofactor (SAH, highlighted in gray). Abbreviation:
Rsub, substrate arginine.
Figure 31. Structural comparison of the active site of rat PRMT1
bound to SAH and substrate arginine (PDB code 1OR8) and human
PRMT5 bound to sinefungin and histone H4 peptide substrate (PDB
code 4GQB).
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Notably, PRMT1, PRMT5, and PRMT6 employ rapid
equilibrium random kinetic mechanisms wherein substrate
binding and product release occur in a random fashion,131,132
although it should be noted that prior work with PRMT6
suggested that this enzyme utilized an ordered kinetic
mechanism in which SAM binds ﬁrst and SAH dissociates
last from the enzyme.133 However, this study only used product
inhibition patterns to assign the order of substrate binding and
product release, and the overall quality of the observed
inhibition patterns is quite poor. Thus, PRMT6, like PRMT1
and PRMT5, most likely binds its substrates in a random
fashion. Notably, though, the PRMT4-catalyzed reaction has
also been suggested to proceed via an ordered sequential
mechanism where SAM binding is the ﬁrst step and SAH is the
last product to leave the enzyme.112d
The PRMT1 catalytic mechanism proceeds via a bimolecular
nucleophilic substitution (SN2) methyl transfer reaction (Figure
33). The two invariant glutamate residues E144 and E153 are
hypothesized to localize the positive charge of the guanidinium
group to one ω-nitrogen atom, thereby leaving a lone pair of
electrons on the other terminal nitrogen to attack the
methylsulfonium group of SAM. Originally, it was proposed
that the substrate guanidinium is deprotonated and thereby
activated by the carboxylate of E144. However, using solvent
isotope eﬀect experiments, Rust et al. suggested that general-
acid/base catalysis is not important for promoting methyl
transfer in PRMT1.134 Instead they proposed that the PRMT1-
catalyzed reaction is primarily driven by proper substrate
guanidinium alignment by E144 and E153 with respect to the
S-methyl group of SAM and that the prior deprotonation of the
substrate guanidinium group is not required for methyl transfer.
Subsequent quantum mechanical (QM) calculations indicated
that E144 abstracts a proton from the reacting arginine
immediately after methyl transfer, consistent with the
mechanism proposed by Rust et al.135 These QM studies also
suggested that the guanidinium loses planarity in the transfer
state, as predicted by the observed inverse solvent isotope
eﬀect.134,135 The positioning of the ω-nitrogen of the
guanidinium group to attack the SAM methyl group ultimately
results in the arginine N-methylation and generation of the
byproduct SAH.
3.3. Is Protein Arginine Methylation a Reversible
Modiﬁcation?
Several PTM regulatory systems such as phosphorylation,
ubiquitination, or lysine acetylation are reversibly regulated;
however, for arginine methylation, PRMTs act as writers, but
the occurrence of a corresponding eraser that clips oﬀ the
methyl group is still controversial. There was a report claiming
that the iron- and α-ketoglutarate-dependent dioxygenase
Jumonji domain 6 (Jmjd6) protein acts as an arginine
demethylase (eraser).136 However, subsequent detailed analyses
revealed that this enzyme is in fact a lysine hydroxylase and
does not erase the methyl mark from methylated arginine
residues.137 As described above, PAD4 was also suggested to
convert methylated arginines to citrulline,38 but this activity is
unlikely physiologically relevant due to the extraordinarily low
activity.19,39b Therefore, PAD activity antagonizes arginine
methylation by competition with PRMTs but does not directly
convert methylarginines into citrulline.19,28,41 Nonetheless, due
to the dynamic appearance and disappearance of methylargi-
nine marks,41,138 the existence of an arginine demethylase is
Figure 32. Structural comparison of the active site pocket of C. elegans
PRMT5 bound to SAH (PDB code 3UA3) and rat PRMT4 (CARM1)
bound to SAH (PDB code 3B3F). The lower images depict the
putative model of the enzyme active site pockets bound to its
products, represented by SAH and SDMA in the case of PRMT5 or
SAH and ADMA for PRMT4.
Figure 33. Proposed catalytic mechanism for type I PRMT enzymes, exempliﬁed by PRMT1.
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very likely.100 Examples for aminomethyl demethylases are
found in nature, and two separate classes of histone lysine
demethylases are known to exist.139 The ﬁrst class was
discovered in 2004 and consists of the lysine-speciﬁc
demethylases (LSDs), which are ﬂavin adenine dinucleotide
(FAD)-dependent amine oxidases that remove mono- and
dimethylation marks (Figure 34A).140 The FAD cofactor
oxidizes the methyllysine to form an imine intermediate,
which is then hydrolyzed to yield unmodiﬁed lysine and
formaldehyde. The resulting reduced FADH2 is reoxidized by
molecular oxygen, thereby forming hydrogen peroxide as a
byproduct. The second group comprises the Jumonji C-
terminal domain (JmjC) family of histone demethylases, which
use iron and α-ketoglutarate as cofactors, thereby acting as
oxygenase enzymes to remove mono-, di-, and trimethyl groups
from methylated lysine residues (Figure 34B).141 The JmjC-
catalyzed demethylation reaction involves oxidative decarbox-
ylation of α-ketoglutarate, coupled to hydroxylation of the
methyl group, generating an unstable hydroxymethylammo-
nium intermediate, which is released as formaldehyde.
3.4. Methylarginine-Binding Proteins
In contrast to the identiﬁcation of an arginine demethylase,
there is strong structural and biochemical evidence to support
the existence of methylarginine readers (Figure 35).107,142 For
example, several members of the Tudor protein family
speciﬁcally recognize methylated arginine residues. These
proteins contain a conserved Tudor domain, which is
responsible for either methylarginine or methyllysine bind-
ing.142c On the basis of sequence analysis, however, it is not
possible to unequivocally predict the binding speciﬁcity of
individual Tudor domains. Structural studies of Tudor domains
revealed that an aromatic cage surrounds the methylarginine,
thereby forming extensive cation−π and hydrophobic inter-
Figure 34. Mechanisms of lysine demethylation. (A) Active site of human LSD1 with bound FAD attached to the mechanism-based histone 3
peptide inhibitor N-methylpropargyl-K4 H3 (PDB 2UXN)230 and proposed mechanism. Note that the covalent inhibitor was further reduced using
NaBH4. (B) Active site of the JMJD2A with bound H3K9me3, nickel, and N-oxalylglycine that both mimic the actual iron and α-ketoglutarate
cofactors, highlighted in green and gray, respectively (PDB 2OQ6),231 and proposed mechanism. Green dashed lines represent CH···O hydrogen
bonds. Abbreviations: FAD, ﬂavin adenine dinucleotide; FADH, reduced ﬂavin adenine dinucleotide; FA, formic acid; aKG, α-ketoglutarate; OGA,
N-oxalylglycine.
Figure 35. Schematic overview of writers and readers of histone
arginine methylation.
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actions with the bound ligand (Figure 36).105 In addition, it was
shown that the hydrophobic cage for methylarginine
recognition is much narrower (diameter ∼7 Å) than the cage
for methyllysine (diameter >8 Å), thus favoring binding of the
planar guanidinium group.105 The structure of ADMA-bound
Tudor domains is a good example of how nature utilizes
noncovalent cation−π interactions to recognize the arginine
guanidinium group.143 In this respect, it was shown that
methylation of arginine residues increases the strength of
cation−π interactions compared to that for unmodiﬁed
arginine.144 Notably, the high aﬃnity and speciﬁcity in the
binding of trimethylated lysine to chromodomains that harbor
similar aromatic cage structure also depend on favorable
cation−π interactions.145 The strong contribution of multiple
cation−π interactions might also provide a plausible mechanism
to exclude an uncharged peptidyl citrulline from binding to
Tudor domains as it cannot form this type of interaction,
although it should be noted that this has not been
systematically tested.
Recently, it was shown that the TDRD3 protein recognizes
ADMA-methylated histone H4 tails via its Tudor domain,
thereby activating transcription.146 Although most of the Tudor
domains prefer SDMA, it was recently shown that TDRD3 also
recognizes ADMA in H3 (H3R17me2a) and H4
(H4R3me2a).146,147 Moreover, it was shown that the PHD
domain of the DNA methyltransferase DNMT3A can bind to
the H4R3me2s suppressive gene expression mark.148 There, it
was proposed that PRMT5 generates H4R3me2s on targeted
promoters, which are recognized by DNMT3A. The recruited
DNMT3A promotes DNA methylation, thereby inducing gene
silencing. However, a subsequent study by Otani et al. could
not conﬁrm any interaction between the DNMT3A PHD
domain and an H4R3me2s peptide.149
3.5. Chemical Probes−Inhibitors for PRMTs
3.5.1. Inhibitors of PRMTs. Since PRMTs aﬀect a plethora
of diﬀerent target genes, it is unsurprising that, when
dysregulated, they play a role in human disease. In fact,
dysregulated PRMT activity has been causally linked to the
development and progression of numerous cancers, as well as
to viral replication and cardiovascular disease. Therefore, the
PRMTs constitute promising targets for drug discovery, and
inhibitor development is at the frontline of current PRMT
research.8b
One of the earliest described PRMT inhibitors to be
discovered is autogenerated by the enzyme during catalysis.
As described above, the methyl donor substrate SAM is
converted to SAH (21) (Figure 37), which represents a potent
feedback inhibitor of PRMT activity, and accumulates as an
inevitable byproduct of protein methylation. In cells, SAH
levels can be raised by blocking its degradation via SAH
Figure 36. SMN Tudor domain bound to the asymmetric
dimethylated arginine residue (PDB code 4A4G). The left panel
illustrates the Tudor domain colored according to its electrostatic
surface potential. The image on the right highlights the ADMA-
interacting residues that form a hydrophobic cage around the
methylated guanidinium group.
Figure 37. Nonselective PRMT inhibitors. Note that adenosine dialdehyde (22) and AMI-1 (25) are both not direct PRMT inhibitors. Adenosine
dialdehyde blocks the activity of SAH hydrolase, which induces an increase in SAH levels, thereby inhibiting PRMT activity. AMI-1 binds to the
histone substrates and prevents recognition by the PRMT enzyme.
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hydrolase. In fact, adenosine dialdehyde (22) is a potent SAH
hydrolase inhibitor that is often used in cell studies to increase
the amount of intracellular SAH. Higher SAH levels in turn
result in feedback inhibition of most SAM-dependent
methylation reactions including PRMT activity. SAM ana-
logues, such as methylthioadenosine (MTA, 23) and sinefungin
(24), also function as general PRMT inhibitors (Figure 37);
however, they exhibit limited speciﬁcity, due to their structural
homology to SAM. Thus, they inhibit numerous other SAM-
dependent methyltransferases, thereby aﬀecting the cellular
methylation of phospholipids, proteins, DNA, and RNA as well.
As such, SAM-mimicking methyltransferase inhibitors display
limited speciﬁcity by indiscriminately inhibiting all SAM-
utilizing enzymes.
To obtain PRMT-selective inhibitors, several approaches,
including both virtual and high-throughput screens, as well as
substrate analogue inhibitor design were conducted. One of the
ﬁrst high-throughput screens directed against the yeast type I
PRMT, Hmt1p, resulted in the identiﬁcation of several arginine
methyltransferase inhibitors, denoted as AMI.150 Most of these
inhibitors were highly nonspeciﬁc and also blocked the activity
of the protein lysine methyltransferases. AMI-1 (25), however,
a symmetric naphthalenesulfonate molecule, inhibited PRMT1
with an IC50 of 8.8 μM but did not diminish the activity of
distinct lysine methyltransferases. In addition, AMI-1 blocked
the activity of PRMT3, PRMT4, and PRMT6. It was also
shown that AMI-1 is cell-permeable and that it inhibits
endogenous PRMT1 activity in a concentration-dependent
manner.150 However, on the basis of circular dichroism,
ﬂuorescence, and absorption spectral analysis, Feng et al.
unequivocally determined that AMI-1, and related naphthale-
nesulfonate derivatives, target the substrate instead of the
PRMT enzyme and are therefore not direct PRMT
inhibitors.151 Notably, AMI-1 forms a complex with an H4
peptide substrate, most likely via bidentate electrostatic
interactions between its sulfonate groups and the arginine
guanidinium groups present in the peptide substrate, thereby
blocking substrate access to the PRMTs.151
Fragment-based virtual screening identiﬁed RM65 (26) as a
cell-permeable PRMT1 inhibitor.152 Docking studies suggest
that 26 is a competitive inhibitor, occupying both the SAM-
binding and the substrate arginine-binding sites. Compound 26
was also shown to reduce histone H4R3 methylation in HepG2
cancer cells at concentrations above 100 μM. Using a similar
virtual docking and pharmacophore-based ﬁltering approach,
the Jung group identiﬁed the diamidine stilbamidine (27) and
allantodapsone (28) as PRMT1 inhibitors.153 Both compounds
are competitive for the protein substrate, but not for the
cofactor SAM. Moreover, these inhibitors are active in a
functional assay of estrogen receptor activation and also
reduced the cellular methylation of R3 in histone H4 at
concentrations below 50 μM while having minor eﬀects on the
lysine methylation at H3K4.153 Further optimization resulted in
the generation of even more potent inhibitors, such as the
dapsone derivative 29, which inhibits PRMT1 with an IC50 of
1.5 μM.154
The Thompson group observed that the SAM congener 5′-
(diaminobutyric acid)-N-(iodoethyl)-5′-deoxyadenosine am-
monium hydrochloride (AAI, 30) blocks PRMT1 activity
with an IC50 of 18.5 μM and a 4.4-fold preference for PRMT1
over CARM1 (Figure 38)155 This compound is thought to
form a reactive aziridinium moiety that is susceptible to
nucleophilic attack.156 Interestingly, upon incubation with
PRMT1 and H4 peptide substrate, this compound reacts with
the incoming arginine substrate (H4R3) in situ in an enzyme-
dependent manner, thereby autogenerating an eﬀective
bisubstrate inhibitor within the enzyme active site (Figure
38). The ability of PRMT1 to chemoenzymatically generate an
eﬀective bisubstrate analogue inspired the development of
deﬁned bisubstrate derivatives. In this respect, the partial-
Figure 38. SAM derivative AAI is transformed in situ to generate a bisubstrate PRMT inhibitor. The gray sphere denotes a peptidyl arginine
substrate.
Figure 39. Bisubstrate-based PRMT inhibitors.
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bisubstrate analogue 31, which comprises an arginine-
containing peptide fragment that was linked to the amino
acid moiety of SAM, was shown to block PRMT1 activity with
an IC50 of 14 μM (Figure 39).
157 This compound shows
limited PRMT selectivity and also blocks PRMT4 and PRMT6
with similar eﬃciency. In addition, Dowden and colleagues
reported the development of SAM derivatives conjugated to a
guanidinium group via varying carbon linkers (32−34).158
Comparison of the generated derivatives revealed that a four-
carbon spacer, present in 33 between the guanidinium group
and the SAM analogue, is most suited for eﬃcient PRMT
inhibition (IC50 = 2.9 μM). Though the selectivity of this
inhibitor for other PRMTs was not evaluated, it did not show
substantial inhibitory activity against the lysine methyltransfer-
ase SET7.158 The Martin group recently developed a partial
bisubstrate inhibitor where the SAM adenosine moiety is
connected to the guanidinium group (35).159 Interestingly, 35
was more potent than the previously described (partial)
bisubstrate inhibitors with IC50 values of 1.3 μM, 560 nM,
and 720 nM for PRMT1, PRMT4, and PRMT6, respectively.
Moreover, this compound did not display any measurable
inhibitory eﬀect on the lysine methyltransferase G9a; however,
it also did not show any inhibitory eﬀect on cell proliferation
using MCF7 and Caco2 cells.159 Although bisubstrate
analogues represent interesting tools to analyze PRMT activity,
they comprise several limitations, including lack of selectivity,
within the PRMT family, and, with respect to peptide-based
bisubstrate inhibitors, undesirable pharmacological properties.
Therefore, recently, great eﬀorts have been taken to yield
potent and isozyme-selective PRMT inhibitors.
The stilbamidine derivative furamidine 36 contains two
amidine moieties and is speciﬁc for PRMT1 with an IC50 of 9.4
μM (Figure 40).160 Another potent PRMT1 inhibitor is a
peptide-based haloacetamidine-containing compound dubbed
C21 (37).161 This compound is derived from the N-terminal
sequence of histone H4 with a chloroacetamidine-modiﬁed
residue in place of H4R3 to serve as a reactive warhead. In
contrast to most other PRMT inhibitors, C21 acts as an
irreversible inhibitor that forms a covalent bond with a hyper-
reactive cysteine residue, C101,162 present in the active site of
the enzyme.163 In addition, despite the presence of a
chloroacetamidine warhead, which is also present in the most
potent PAD inhibitors (see above), C21 is selective for PRMT1
(IC50 = 1.8 μM) and displays poor inhibitory activity toward
the PAD enzymes (IC50 for PAD4 = 145 μM).
161 Notably, C21
selectively inhibits cellular PRMT1 activity over PRMT4 when
delivered into cells with peptide transfection reagents.161
However, C21 is only ∼5-fold more selective for PRMT1
over PRMT6. To screen for more selective PRMT1 inhibitors,
Bicker and colleagues employed a combinatorial peptide library
approach.164 The identiﬁed hit, denoted C21-1F (38), contains
a phenylalanine instead of a glycine at the R-1 position (Figure
40). Although C21-1F is slightly less potent than C21, it is 3
times more selective for PRMT1 over PRMT6, indicating that
residues around the substrate arginine might be exchanged or
modiﬁed to develop isozyme-selective PRMT inhibitors.
With respect to PRMT3, Siarheyeva et al. employed a library
screening approach to identify selective inhibitors targeting this
enzyme.165 Optimization of the initial hit compounds revealed
inhibitor 39.166 Notably, this inhibitor is noncompetitive with
respect to both SAM and the peptide substrate and binds to an
allosteric site present in PRMT3 (Figure 41). This compound
is highly selective for PRMT3, and detailed structural analyses
showed that 39 binds to an allosteric pocket at the base of the
dimerization arm between two PRMT3 subunits. There, 39
interacts with and distorts the activation helix, which is critical
for proper SAM binding. It is thought that 39 induces
conformational constraints on this α-helix that prevent
formation of a catalytically competent state.166 The isoquino-
line moiety of 39 forms a buried hydrogen bond with T466, the
Figure 40. PRMT1-selective inhibitors.
Figure 41. Allosteric PRMT3 inhibitor SGC707. Crystal structure of dimeric PRMT3 bound to inhibitor 39 (PDB code 4RYL). SGC707 (gray)
binds an allosteric site located at the interface between two PRMT3 protomers. Hydrogen bonds of <3.5 Å are represented as dashed black lines.
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urea group forms hydrogen bonds with the side chains of E422
and R39, and the pyrrolidine amide pushes against the α-helix
(Figure 41). To test the in vivo eﬃcacy, 39 was evaluated for
target engagement using an InCELL Hunter assay. There, it
was shown that 39 stabilized PRMT3 in HEK293 cells with an
EC50 value of 1.3 μM. Moreover, 39 can block the PRMT3-
dependent dimethylation of endogenous histone 4 at H4R3
with an IC50 of 225 nM. These data demonstrate that 39 is a
potent, selective, and cell-active allosteric inhibitor of PRMT3
that is suitable for further cell or animal studies.
High-throughput screening eﬀorts also led to the identi-
ﬁcation of pyrazole and benzimidazole derivatives as potent
PRMT4 inhibitors.167 Subsequent optimization of the initial hit
compounds resulted in nanomolar inhibitors such as the indole
derivative 40 and the pyrazole derivative 41, which possess IC50
values of 30 and 27 nM, respectively (Figure 42).168
Interestingly, both of these inhibitors bind to the substrate
arginine-binding cavity of PRMT4 and require the presence of
bound cofactor SAH (Figure 42).168 Structural studies of
PRMT4 in complex with sinefungin and 40 revealed that the N-
methylethanamine moiety of the inhibitor is directed toward
the bottom of the arginine-binding cavity and directly interacts
with the active site residue E258. The piperidine group is
positioned at the entrance of the active site cavity and hydrogen
bonds to H415 of the THW loop, whereas the indole moiety
makes hydrophobic interactions with several aromatic side
chains of PRMT4 and forms a water-mediated hydrogen bond
to the main chain carbonyl of K471 and the side chain of N266.
The crystal structure of PRMT4 bound to 41 revealed that the
terminal L-alaninamide moiety mimics the arginine guanidinium
group and makes several polar interactions with PRMT4,
including the carboxyl groups of the double E-loop residues
E258 and E267. In addition, the alanylmethyl group of 41
forms CH···O hydrogen bonds to the hydroxyl oxygen of Y154
and the backbone carbonyl oxygen of M260, while the carbonyl
oxygen of the L-alaninamide hydrogen bonds with one of the
imidazole nitrogens of H415. Notably, the (triﬂuoromethyl)-
pyrazole, 1,3,4-oxadiazole, and indole scaﬀolds are thought to
mainly interact with PRMT4 via shape complementarity rather
than by polar interactions, except for two hydrogen bonds
formed between the side chain of Y262 and the oxadiazole
oxygen atom and between the hydroxyl og Y477 and a ﬂuorine
of the triﬂuoromethyl group.
Very recently, researchers from Epizyme developed selective
PRMT5 inhibitors containing a di- or tetrahydroisoquinoline−
hydroxypropyl−arylcarboxamide scaﬀold.169 One of the most
eﬀective compounds, EPZ015666 (Figure 43), was shown to
act as a very potent (Ki = 5 nM), selective (>20000-fold
compared to other protein methyltransferases), and orally
bioavailable inhibitor of PRMT5.170 Interestingly, the tetrahy-
droisoquinoline moiety of 42 is thought to directly bind to the
characteristic F327 residue that is present in PRMT5 but absent
in other PRMTs via π−π stacking interactions.170 In addition, it
was demonstrated that 42 reduces cellular SDMA levels in Z-
138 cell lines with an IC50 of 44 nM and displays robust
antitumor activity in mantle cell lymphoma (MCL) xenograft
mouse models. Thus, EPZ015666 has cellular activity and in
vivo eﬃcacy and represents a promising lead compound for the
development of PRMT5 inhibitors as potential cancer
therapeutics.
In 2015, Alinari and colleagues also reported the discovery of
a selective PRMT5 inhibitor employing a structure-based
virtual screening approach.171 After initial cell testing assays,
CMP5 (43) was identiﬁed as the top hit and used for further
characterizations. It was shown that 43 is selective for PRMT5
and does not block PRMT1, PRMT4, or PRMT7 at
concentrations below 100 μM. Moreover, on the basis of
modeling studies, this compound is predicted to occupy the
SAM-binding pocket via its carbazole ring, while the pyridine
ring is thought to form π-stacking interactions with the
characteristic F327 of PRMT5. Inhibitor 43 was selectively
toxic to lymphoma cells and killed Pfeiﬀer cells and SUDHL2
cells with IC50 values of 30 and 35 μM, respectively.
171 In
addition, CMP5 treatment reduces the cellular level of
H4R2me2s as well as H3R8me2s marks, thus highlighting its
cellular eﬃcacy.
3.5.2. Chemical Probes for the PRMTs. Since C21 is an
irreversible, covalent, and highly selective PRMT1 inhibitor, it
was adapted for use as a chemical probe of PRMT1 activity by
attaching ﬂuorescein (F-C21, 44) and biotin (B-C21, 45)
reporter tags (Figure 44).172 Although F-C21 labels recombi-
nant PRMT1, the ﬂuorescent probe cannot detect cellular
PRMT1, likely due to low levels of the active protein. However,
B-C21 can eﬃciently be used to label and isolate endogenous
PRMT1 from MCF-7 whole cell extracts. Notably, using B-C21
Figure 42. PRMT4 (CARM1)-selective inhibitors. The top panel
illustrates the structural characterization of the indole inhibitor 40
bound to PRMT4 (PDB code 2Y1W). The lower image represents the
crystal structure of PRMT4 bound to the pyrazole inhibitor 41 (PDB
code 2Y1X). Dashed green lines indicate CH···O hydrogen bonds,
whereas other polar contacts of <3.5 Å are represented as dashed black
lines.
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as an ABPP, it was shown that cellular PRMT1 activity is
regulated in response to estrogen. Speciﬁcally, the amount of
active PRMT1 isolated from nuclear extracts is reduced after
estrogen treatment, suggesting that PRMT1 activity is
negatively regulated in a manner that ultimately precludes the
enzyme from interacting with its substrates (mimicked by B-
C21).172 Interestingly, the subcellular localization of the
PRMTs also appears to be altered in cancer cells (see
below), suggesting that the non-nuclear eﬀects of the PRMTs
may be more important than previously thought.
Since the ﬂuorescent conjugate F-C21 acts as a potent
PRMT1 inactivator, it could also be used in Fluopol-ABPP-
based HTS approaches to identify speciﬁc PRMT1 inhibitors in
a manner similar to that described for the PAD enzymes (see
above). In this respect, Dillon and colleagues adapted a
cysteine-reactive maleimide conjugated to AlexaFluor488 as an
ABPP to screen for PRMT1 inhibitors.173 This probe, although
much less speciﬁc than F-C21, can label PRMT1 by forming a
covalent bond with a hyper-reactive cysteine residue, C101,162
that is located in the SAM-binding pocket close to the purine
ring. Using this Fluopol-ABPP assay, they identiﬁed two potent
PRMT1 inhibitors, 46 and 47 (Figure 45), that also block
PRMT8 activity but not PRMT4 activity.173 Both of these
compounds are nitroalkenes and are expected to react with the
cysteine residue in PRMT1. Notably, PRMT8 also possesses a
cysteine residue in its SAM-binding pocket, whereas PRMT4
does not.
3.6. Physiological Role of Histone Arginine Methylation
PRMTs methylate numerous cellular protein substrates,
including nuclear proteins such as transcription factors, other
coregulators, and histones. The importance of this PTM to
cellular growth is probably best exempliﬁed by the fact that
both PRMT1 and CARM1 mouse knockouts are embryonically
lethal. The currently identiﬁed sites of histone methylation are
H2AR3 and R11, H2BR29, R31, and R33, H3R2, R8, R17, and
R26, and H4R3, R17, R19, and R23 (Figure 46). The diversity
of arginine methylation sites on histone proteins provides
Figure 43. PRMT5-selective inhibitors.
Figure 44. Probes for PRMT1. The amidine group is highlighted in
blue, whereas the reporter tags (biotin or ﬂuorescein) are marked in
red. IC50 values for the PRMTs were determined after incubation of
the enzyme with 15 μM 14C-methyl-SAM for 10 min at 37 °C.
Figure 45. Nitroalkenes as cysteine-reactive PRMT1 inhibitors.
Figure 46. Arginine methylation sites in histone proteins. Abbrevia-
tions: a, asymmetric dimethylation; s, symmestric dimethylation; m,
monomethylation. Color code: green, gene activation; red, gene
repression; yellow, gene activation or repression, or unknown.
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multiple routes to directly link arginine methylation to the
epigenetic regulation of gene expression (Figure 46). In
addition, the methylation of arginine residues in several
transcriptional coactivators (e.g., the histone acetyltransferases
p300 and CBP) provides an indirect route to inﬂuence the
epigenetic state of aﬀected genes. Originally, it was assumed
that the methylation of histone arginine residues was associated
with gene activation, as the dimethylation of histone H4R3 by
PRMT1 facilitates transcriptional activation by a variety of
nuclear hormone receptors.174 More recently, however, it
became apparent that arginine methylation can be either an
activating or a repressing mark that regulates the expression of
multiple genes. Below we highlight several examples of PRMT-
mediated histone methylation events that are correlated with
the activation and repression of gene transcription.
3.6.1. Methylation of H2AR3. H2AR3 methylation can be
catalyzed by PRMT1, PRMT5, PRMT6, or PRMT7, generating
ADMA (PRMT1 and PRMT6), SDMA (PRMT5), or MMA
(PRMT7). The eﬀects of these methylation events are varied.
For example, in mouse ES cells, PRMT5 expression and activity
are upregulated and the enzyme was shown to symmetrically
dimethylate H2AR3. This event helps maintain pluripotency by
repressing diﬀerentiation genes, including Fgf5, Gata4, Gata6,
and HoxD9.175 This report also indicated that PRMT5 is
critical for embryonic stem cell (ESC) generation, as no ESCs
were generated in Prmt5−/− mouse embryos.175 However, in a
separate study investigating human ESCs, PRMT5 knockdown
had no eﬀect on pluripotency, as evidenced by the fact that the
PRMT5 knockdown cells and wild-type cells had similar RNA
levels for genes associated with multiple tissue types.176
PRMT5 knockdown did, however, correlate with the repression
of 78 genes. Notably, only two of these genes are known
developmental genes, whereas the rest are associated with basic
cellular processes.176 These results illustrate the diﬀerences
between the human and mouse epigenetic landscape.
PRMT7 also methylates H2AR3 in response to DNA
damage to repress the transcription of the DNA polymerases
POLD1 and POLD2. Importantly, when PRMT7 was knocked
down in a cellular model, cells were more resistant to DNA
damage due to the derepression of DNA damage response
genes such as POLD1 and POLD2.177 Collectively, these results
illustrate the importance of isozyme-speciﬁc PRMT inhibitors.
In this case, if a PRMT inhibitor were used in combination with
a DNA-damaging agent, inhibition of PRMT7 could promote
tumor resistance to the chemotherapeutic drug.
3.6.2. Methylation of H2AR11 and R29. H2AR3, R11,
and R29 were all shown to be methylated in a proteomic study
of histones extracted from HeLa cells. Notably, H2AR29 was
found to be methylated at sites known to be associated with
PRMT6-mediated gene repression, suggesting that PRMT6 is
able to asymmetrically dimethylate H2AR29 in vivo.178 These
genes include EIF1b, MMP9, THBS1, and TNFRSF11B.
THBS1 is of particular interest as it is dysregulated in a variety
of cancers, speciﬁcally playing a role in angiogenesis.178
3.6.3. Methylation of H3R2. On the basis of current data,
histone H3 is the most heavily modiﬁed histone, and the
methylation of arginine residues in this protein follows this
trend. PRMT6 dimethylates H3R2, and this modiﬁcation alters
the binding of several eﬀector proteins that typically bind
H3K4Me. These eﬀectors, including JMJD2, and several
Tudor- and PHD-domain-containing proteins, play a variety
of roles in gene activation. It follows then that H3R2
methylation causes a change in the gene activation proﬁle of
the cell. These changes were characterized prominently by
investigating the downstream eﬀects of one particular eﬀector
protein, WDR5, which is an integral component of the MLL
complex that catalyzes the methylation of H3K4. Interestingly,
this WD40-repeat protein was shown to have decreased binding
upon H3R2 dimethylation, resulting in a reduction in the
activation of a number of target genes, including HoxA5 and
cyclin D1.179 Interestingly, PRMT6 is able to methylate H3R2
regardless of the methylation state of H3K4, suggesting that the
methylation of H3R2 has a dominant eﬀect on H3K4
methylation.
PRMT5 also symmetrically dimethylates H3R2, and this
modiﬁcation promotes chromatin remodeling, exposing a
binding site for a transcription factor called CREB (cAMP-
response-element-binding protein). CREB is then phosphory-
lated by PKA, allowing for the activation of target genes
involved in glucose metabolism, including G6pc, Pck1, and
Ppargc1a.180 Expression of CARM1 is similarly necessary for
expression of glucose homeostasis factors, including Gys1,
Pgam2, and Pgym. This role, however, was not linked to a
speciﬁc histone methylation event.181
3.6.4. Methylation of H3R8. PRMT5 has also been
implicated in metabolic regulation via the dimethylation of
H3R8. In both cell culture and primary adipocytes, ChIP results
show that PRMT5 associates with PPARγ2 and PPARγ2-
responsive promoter sequences, activating adipogenesis. In type
2 diabetes, PRMT5 regulates metabolic signals during a fasting
state by associating with CRTC2, which directs it to target
genes.182
3.6.5. Methylation of H3R17 and R26. CARM1 activity
on H3R17 also regulates eﬀector binding. In a recent study,
asymmetric dimethylation of this site not only blocked
association of the TIF family of corepressors, but prevented
deacetylation by abrogating the interaction of H3 with the
NuRD complex.183 Like PRMT5, CARM1 was also found to
maintain pluripotency in mouse ESCs. Notably in this study,
ChIP experiments using antibodies for CARM1 as well as for
two diﬀerent methylated H3 substrates, H3R26me2a and
H3R17me2a, showed that CARM1 is recruited to the
promoters of a variety of genes involved in diﬀerentiation.
This more precisely implicates not only CARM1 but histone
modiﬁcation in gene activation.184 In another study, CARM1
was shown to be recruited to the creatine kinase promoter
during skeletal myogenesis.185 Further studies indicate that
CARM1 is speciﬁcally expressed during diﬀerentiation and
recruited to the nucleus and subsequently to chromatin.185
Knockdown studies show that, in the absence of CARM1, the
levels of other members of the transcription factor complex
associated with creatine kinase activation are not expressed,
giving another facet of the role of CARM1 in this process.
Together, this study shows an enhancing role for CARM1 in
muscle diﬀerentiation.185
3.6.6. Methylation of H4R3. H4R3 is methylated by a
number of PRMTs, including PRMT1, PRMT5, and PRMT6.
The ﬁrst indication that the methylation of this residue could
alter gene transcription began with reports investigating
PRMT1 activity on puriﬁed H4 with varied levels of lysine
acetylation.174 These studies showed that PRMT1 methylates
unacetylated histones more eﬃciently than acetylated histones.
This allowed Wang et al. to conclude that asymmetric
dimethylation of H4R3 was likely a transcriptional activating
event that promoted the acetylation of histone H4 by the
histone acetyltransferase p300 to activate gene expression.174
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The ﬁrst report to clearly identify a role for a PRMT in
tumorgenesis came from a study showing that PRMT1
methylates H4R3 as a part of the MLL complex in
hematopoietic cells.186 With the introduction of the full MLL
complex, these cells showed enhanced self-renewal when
compared to those with an MLL complex with a catalytically
dead PRMT1. This implicates PRMT1, speciﬁcally its role in
dimethylating H4R3, in cell survival.186
By contrast with the results obtained for PRMT1, the
symmetric dimethylation of H4R3 by PRMT5 is generally a
repressive mark. For example, in an early study of arginine
methylation, PRMT5 was shown to associate with the SWI/
SNF (switch/sucrose nonfermentable) chromatin remodeling
complex as well as with the Brg1 complex. As a part of this
complex, PRMT5-mediated methylation of H4R3 displayed a
repressive functionality speciﬁcally on the c-Myc target gene
Cad.187 This report further implicated PRMT5 as playing a role
in oncogenesis as well as being a part of a larger chromatin-
modifying complex and thereby working in collaboration with
other epigenetic transformations. A later bioinformatics study
using ChIP-seq data analysis of histone methylation found
PRMT5-mediated H4R3 dimethylation to be the second most
repressive mark of the 20 lysine and arginine methylation
events tested. Also shown in this study was the dependence of
DNMT3A-mediated DNA methylation on the symmetric
dimethylation of H4R3.188 DNA methylation by DNMT3A is
also known to be a transcriptionally repressive modiﬁcation.148
H4R3 methylation also aﬀects the binding of the eﬀector
proteins SRP68/72 to H4. Interestingly, both asymmetric
dimethylation and symmetric dimethylation of H4R3 inhibit
the binding of the SRP68/72 heterodimer to chromatin both in
vitro and in cells.189
3.7. Nonhistone Methylation in Epigenetic Regulation
PRMT1 also methylates ERα at R260, within its DNA-binding
domain. This methylation event occurs in response to estradiol
and allows for the association of ERα with PI3K and Src,
leading to Akt1 activation. Moreover, in highly malignant ER+
breast cancer samples, ERα was found to be hypermethylated,
suggesting a role for PRMT1 in breast cancer.138b BRCA1 is
also methylated by PRMT1, which alters its binding to a variety
of promoters, leading to increased binding to the APEX, ARHG,
and GADD45G promoters, and a decrease in binding to ESR2,
SREB, and FGF9 promoters.190
PRMT1 also aﬀects mRNA processing by methylating FUS
(fused in sarcoma).191 FUS is an mRNA-binding protein that is
important for mRNA processing and shuttling RNAs from the
nucleus to the cytoplasm. However, nuclear import of FUS
relies upon its binding to transportin 1. The FUS/transportin 1
interaction is abrogated by a PRMT1-mediated methylation
event, causing FUS to be traﬃcked to inclusion bodies that are
found in amyotrophic lateral sclerosis (ALS) patients. PRMT1
knockdown increases FUS/transportin 1 binding as well as the
nuclear localization of FUS.191
PRMT5-mediated methylation of the tumor suppressor p53
also helps to regulate the expression of p53 target genes. The
sites of modiﬁcation were mapped to R333, R335, and R337,
and methylation at these sites induced cell cycle arrest, whereas
the deletion of PRMT5 induced apoptosis.192 These data
indicate that PRMT5-mediated methylation of p53 causes a
change in the response to DNA damage, inducing cell
proliferation.192 In a later study, the role of PRMT5 in p53
signaling was further investigated. Here, PRMT5 was found to
be essential for p53 stability as well as for the expression of two
p53 target genes, MDM2 and p21.193
3.8. Arginine Methylation in Cancer
Dysregulated PRMT expression and activity have been
observed in a variety of cancers. Speciﬁcally, PRMT1,
PRMT2, PRMT3, PRMT4, PRMT5, PRMT6, and PRMT7
have been shown to be overexpressed or otherwise contribute
to tumorigenesis, while PRMT8 and PRMT9 have not yet been
implicated in oncogenesis.
3.8.1. PRMT1 in Cancer. Recent studies have linked the
increased expression of diﬀerent PRMT1 splice variants (i.e.,
PRMT1v1 and PRMT1v2) to enhanced malignancy and poor
prognosis.194 In one study, based on immunohistochemistry of
primary tumor samples, overall PRMT1 expression was linked
to the patient’s age, menopausal status, and progesterone
receptor status.194a In the same study, low expression levels of
PRMT1v1 were associated with increased survival. This
research found no link between PRMT1v2 levels and survival
rate.194a However, in a cell-based study using MCF7 cells,
speciﬁc knockdown of PRMT1v2 increased apoptosis. Sim-
ilarly, induced expression of PRMT1v2 promoted cell invasion
in nonaggressive cell lines; this eﬀect was not achieved by
overexpressing other splice variants of PRMT1.194b Interest-
ingly, both of these papers stress the importance of PRMT1 as
a cytosolic methyltransferase and both report that PRMT1 was
shown to be more malignant when expressed in the
extranuclear environment. While the role of PRMT1 as a
histone arginine methyltransferase has been clearly described in
the literature, the eﬀect of arginine methylation on general cell
signaling is only beginning to be explored.
Dysregulation of PRMT1 has also been linked to breast
cancer and leukemia, again suggesting that it is a potential
therapeutic target.186 As mentioned previously, asymmetric
dimethylation of H4R3 upregulates the expression of estrogen
receptor target genes. While this response was ﬁrst attributed to
PRMT1, the increased expression of estrogen receptor target
genes was later found to be promoted by either PRMT1 or
CARM1.138a In this report, the protein complexes that associate
with the pS2 promoter were identiﬁed by ChIP and reChIP
analysis. In two of the six complexes, a type 1 PRMT was
found, either PRMT1 or CARM1, but never both. In one of
these complexes, PRMT1 and CARM1 were interchangeable.
This complex, notably, also contains histone acetyltransferases.
The other found complex only contained PRMT1 but also
SWI/SNF chromatin remodeler proteins Brg1 and Ini1.138a
3.8.2. PRMT2 in Cancer. PRMT2 is also implicated in
breast cancer relating to its ability to act as a transcriptional
coactivator for ERα.195 In breast cancer cell lines, the levels of
PRMT2 and a splice variant, PRMT2L2, were shown to be
increased in ER+ lines. Upon overexpression of PRMT2L2,
increased expression of ERα target genes was observed.195 It
was later observed that diﬀerent splice variants of PRMT2 have
a distinct subcellular localization.
3.8.3. PRMT3 in Cancer. PRMT3 has been shown to be
regulated post-transcriptionally by a tumor suppressor protein,
DAL-1/4.1B, which inhibits its methyltransferase activity both
in vitro and in cell culture.196 Overexpression of DAL-1/4.1B in
MCF7 cells reduces PRMT3-catalyzed methylation of a variety
of unidentiﬁed cellular proteins. As DAL-1/4.1B has been
shown to have an antiproliferative role, this activity indirectly
implicates PRMT3 in oncogenesis.196
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3.8.4. PRMT4/CARM1 in Cancer. CARM1 levels have
been shown to be increased in colon, prostate, and breast
cancer.197 Like PRMT1, CARM1 plays a role in ER+ breast
cancer by activating ERα target genes. Furthermore, CARM1 is
necessary for this activation event as knockdown of CARM1
abrogates the estrogen response in mouse embryos.198 CARM1
has also been shown to be a marker for well-diﬀerentiated
breast cancer, suggesting that CARM1 plays a role in
reprogramming the epigenome of breast cancer cells. Over-
expression of CARM1 in MCF7 cells causes a change in
morphology as well as a change in the estradiol-induced gene
signature.197c In another breast cancer study, CARM1 was
shown to be necessary for E2F1 expression. E2F1, in turn, is
required for cyclin E1 expression. The cyclin E1 promoter has
high levels of both H3R17me2a and H3R26me2a, both of
which are reduced upon CARM1 knockdown.199
CARM1 is also necessary for NFκB target gene expression as
shown in MEF cells by CARM1 knockdown.200 NFκB is a
transcription factor responsible for the regulation of genes
involved in inﬂammation and cell survival. The eﬀect of
CARM1 was linked to H3R17me2a, though investigation into
the potential role of H3R26me2a was not performed. These
studies also showed a link between CARM1 and p300
acetyltransferase activity in NFκB recruitment and gene
activation. Both enzymes are critical for this event.200
3.8.5. PRMT5 in Cancer. PRMT5 methylates both H4R3
and H3R8 in chronic lymphocytic lymphoma, causing tran-
scriptional silencing of known target genes Rb1, Rbl1, and
Rbl2.201 Knockdown of PRMT5 in a B-CLL cell line model
decreases H4R3 and H3R8 dimethylation, increases protein
expression of RBL2, and inhibits cell proliferation.201
Furthermore, PRMT5 overexpression has been linked to a
number of cancers, including colon, lung, astrocytoma, and
ﬁbrosarcoma.202 Although it is unclear how PRMT5 promotes
tumorigenesis, PRMT5 does regulate eIF4E expression and p53
function as a prosurvival factor.193 PRMT5 also associates with
the SWI/SNF chromatin remodeling proteins, and this
interaction has been suggested to be causal in dysregulating
the expression of tumor suppressor genes, including ST7 and
NM23.203 PRMT5 has also been shown to methylate NF-κB,
promoting its gene regulation functionality in a colon cancer
cell model. By mutating the target arginine on NF-κB to a
lysine residue and therein blocking the ability of PRMT5 to
methylate NF-κB, a more dramatic dysregulation of gene
regulation was observed than by knocking down PRMT5. This
indicates the necessity of arginine methylation for NF-κB
activity.202a
Many of the functions of PRMT5 have been attributed to
cytosolic and other nonhistone targets of arginine methylation.
While PRMT5, as with the other isozymes, was initially
characterized as a histone-modifying enzyme, the role of
PRMT5 in the cellular environment is constantly evolving and
appears to reside more frequently in the cytoplasm, not the
nucleus. For example, Shilo et al. showed that PRMT5 mRNA
and protein levels are dramatically increased in lung carcinoma
tissues over normal lung tissues.202b Along with this trend,
dimethylation of H4R3 also increases, illustrating the role of
PRMT5 in tumor suppression. However, the more striking
trend from this report indicates that there is more cytoplasmic
PRMT5 present not only when comparing cancerous to normal
lung tissues, but also in higher grade tumors with poorer
prognosis.202b
3.8.6. PRMT7 in Cancer. As described previously, PRMT7-
mediated methylation of H2AR3 aﬀects DNA damage repair.
The eﬀects of inhibiting PRMT7 are complex and could result
in resistance to certain chemotherapeutics.177 For these
reasons, isozyme-speciﬁc PRMT inhibitors are essential.
3.9. Arginine Methylation in Atherosclerosis
Nitric oxide (NO) is a regulator of vasodilation known to be
integral to cardiac health. The free amino acid L-arginine is the
precursor for the generation of NO by the nitric oxide synthase
(NOS) family of enzymes. However, when excess ADMA is
present in the system due to the breakdown of proteins
containing ADMA, this serves as an inhibitor of the NOS
enzymes, lowering the production of NO.204 In the absence of
L-arginine or presence of ADMA, NOS can also produce
superoxide, which can have the opposite physiological eﬀect
compared to NO.205 In patients with heart disease, PRMT1 is
observed at elevated levels, as well as a lowered expression of
DDAH, which metabolizes ADMA. Both of these factors cause
increases in ADMA levels and decreased vasodilation.206
4. NONCANONICAL HISTONE ARGININE
MODIFICATIONS
4.1. Protein Arginine Phosphorylation
The phosphorylation of arginine residues in histone H3 was
ﬁrst reported in 1994.207 Although the underlying kinase could
not be identiﬁed, using a partially puriﬁed kinase fraction
derived from nuclear cell extracts of mouse leukemia cells, it
was shown that histone H3 can be arginine phosphorylated at
R2 as well as R128, R129, and R131 in the C-terminus of the
protein.207 This modiﬁcation introduces signiﬁcant negative
charge into the histone that undoubtedly would inﬂuence its
DNA-binding ability and thereby chromatin structure. In
contrast to other phosphorylated residues that are stable
under acidic conditions (e.g., phosphoserine, phosphothreo-
nine, and phosphotyrosine; O-phosphorylations), phosphoargi-
nine, like other N-linked phosphorylation events, is an acid-
labile modiﬁcation. Therefore, current methods to directly
detect protein arginine phosphorylation are sparse, and care has
to be taken to preserve the acid-labile phospho mark during
sample preparation and analysis.208
Although the molecular identity of the responsible eukaryotic
protein arginine kinase is still unclear, it was recently
demonstrated that protein arginine phosphorylation also occurs
in bacteria.208a The underlying protein arginine kinase (PAK)
was identiﬁed as McsB (EC 2.7.14.1) (Figure 47).208a This
enzyme shows close homology to guanidine phosphotransfer-
Figure 47. Protein arginine kinase McsB transfers the γ-phosphoryl
group from ATP onto the arginine guanidinium group. The generated
phosphoarginine residue can be hydrolyzed by the protein arginine
phosphatase YwlE.
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ase enzymes such as creatine kinase and L-arginine kinase.
Guanidine phosphotransferases are typically involved in energy
homeostasis and shuttle the γ-phosphate from ATP onto small-
molecule guanidine-containing compounds that serve as
chemical energy storage devices in cells relying on high rates
of energy turnover such as muscles and neurons.209
McsB shares several highly conserved residues which are
important for nucleotide and substrate guanidinium binding
with other guanidine phosphotransferases. However, it lacks the
entire N-terminal domain that is critical for trapping small-
molecule substrates, such as the amino acid L-arginine, thereby
allowing larger peptidyl substrates to enter the active site.208a
Besides McsB’s preference for peptidyl arginine residues, the
catalytic mechanism is thought to be similar to that of L-
arginine kinases that employ a direct, in-line phosphoryl
transfer between ATP and the guanidinium group (Figure
48A). Notably, it was shown that L-arginine kinase binds
arginine and ATP randomly, i.e., without a speciﬁc order, to the
active site and that the resulting products phosphoarginine and
ADP are individually released.210 Moreover, structural analysis
of arginine kinase bound with a transition-state analogue,
composed of nitrate, ADP, and L-arginine, revealed that ﬁve
arginine residues form a dense network of electrostatic
interactions with the phosphate groups and the γ-phosphate
mimicking nitrate (Figure 48A).211 In addition, a tightly bound
magnesium ion, which is essential for catalysis, is thought to
coordinate all three ATP phosphate groups to properly orient
the γ-phosphate for the transfer reaction to occur.
The substrate arginine is aligned between two carboxylate
groups originating from E225 and E314 that are both thought
to act as general bases. However, mutagenesis studies suggest
that base catalysis by these residues may enhance the catalytic
rate but is not absolutely essential.212 It was suggested that
proper substrate prealignment might be more important than
acid/base chemistry, electrostatics, or other potential eﬀects.212
Due to the polarization of the guanidinium group by the two
glutamate residues, the substrate arginine Nω atom is highly
nucleophilic and predisposed to attack the electrophilic
phosphorus of the ATP γ-phosphate in a classical SN2 reaction.
In addition, the positive charges of several arginine residues and
Figure 48. (A) Active site of L-arginine kinase with bound ADP, nitrate, and L-arginine (PDB code 1BG0) and proposed reaction mechanism. Note
that several arginine residues were omitted in the proposed reaction scheme for clarity. (B) Active site of YwlE C7S with bound peptidyl arginine and
containing a phosphorylated S7 residue, which mimics the thiophosphate reaction intermediate generated after the ﬁrst SN2 reaction (PDB code
4KK4). Residue R149* originates from a symmetry-equivalent molecule. Polar contacts of <3.5 Å are represented as dashed lines. The proposed
catalytic mechanism for the PAP enzyme YwlE is shown on the right side. The guanidinium group of the incoming phosphoarginine substrate is
colored in blue, whereas the phosphoryl group is shown in red.
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the magnesium ion pull electrons toward the phosphate
oxygens, away from the phosphorus, thereby increasing its
electrophilicity.
Recently, a corresponding protein arginine phosphatase
(PAP), YwlE (EC 3.9.1.2), was identiﬁed that can hydrolyze
the phosphoramidate (P−N) bond of phosphoarginine, thereby
releasing unmodiﬁed arginine (Figure 47).213 Notably, YwlE
shares homology with the protein tyrosine phosphatase (PTP)
family and utilizes a similar catalytic mechanism. In contrast to
other PTP members, YwlE employs a dual size and polarity
ﬁlter to select phosphoarginine residues.213a The highly polar
substrate guanidinium group is sandwiched between the
carboxylate of D118 and the hydroxyl of T11 and further
stabilized by cation−π interactions with the phenyl ring of F120
(Figure 48B). The molecular mechanism of phosphoarginine
hydrolysis consists of a two-step process comprising two
consecutive SN2 reactions (Figure 48B).
213a The incoming
phosphoarginine phosphoryl group forms a bidentate bond
with the guanidinium group of R13, whereas the phosphoargi-
nine guanidinium group is clamped between the hydroxyl
group of T11 and the carboxyl group of D118. The phosphorus
atom of the substrate molecule is attacked by the highly
nucleophilic active site cysteine residue C7, forming a
thiophosphate reaction intermediate. This reaction is accom-
panied by the protonation of the arginine leaving group by
D118. Subsequently, an incoming water molecule is deproto-
nated by D118, and the water-derived nucleophilic hydroxyl
anion attacks the phosphocysteine residue, performing the
second SN2 reaction, thereby releasing the phosphate ion and
regenerating the active C7 thiolate anion. The active site
cysteine was shown to be essential for catalysis and subject to
oxidative regulation by the formation of a disulﬁde bridge with
an adjacent backdoor cysteine.214
4.1.1. Physiological Role of Histone Arginine Phos-
phorylation. As shown by Wakim et al., histone H3 is subject
to arginine phosphorylation by a Ca2+-calmodulin-dependent
kinase derived from mouse leukemia cells.207 It was also
demonstrated that in vivo 32P incorporation into H3 in rat
heart endothelial cells results in phosphorylation of a basic
amino acid in quiescent but not in dividing cells.215 This Ca2+-
calmodulin-dependent kinase is present in nearly equal
amounts in both quiescent and dividing cells; however, the
histone H3 phosphorylating activity was 20−100-fold higher in
quiescent cells.215 In addition, it was suggested that
phosphorylation of histone H3 was involved in cell cycle exit.
The studies by Wakim et al. have, however, not been
followed up, and there is still some uncertainty about the
existence of a eukaryotic protein arginine kinase. Notably, the
phosphorylation of arginine residues was solely derived from
indirect methods, including the acid lability of 32P radiolabeling
and a missing signal for arginine using Edman sequencing.
However, to unequivocally prove the presence of phosphoargi-
nine in histone proteins, direct phosphoarginine detection
methods such as recently optimized mass spectrometry
techniques or 31P NMR analysis should be employed.208a,216
4.2. Histone Arginine ADP-Ribosylation
ADP-ribosylation is a covalent PTM which is catalyzed by
ADP-ribosyltransferases (ARTs) and is involved in several
cellular processes such as cell cycle regulation and DNA
damage response, replication, or transcription. The generation
of ADP-ribosylated proteins requires nicotinamide adenine
dinucleotide (NAD+) as a cofactor and leads to the formation
of nicotinamide (Figure 49). ADP-ribosylation was shown to be
reversibly regulated by the hydrolysis of the ADP-ribose group
catalyzed by ADP-ribosyl hydrolase (ARH) enzymes. ARTs can
either attach mono-ADP-ribosyl groups (catalyzed by mARTs)
or poly-ADP-ribosyl groups (catalyzed by pARTs). In contrast
to mARTs that only transfer a single ADP-ribose moiety onto a
speciﬁc amino acid side chain, pARTs (also known as poly-
ADP-ribose polymerases or PARPs), additionally catalyze the
elongation and branching of ADP-ribose units on ADP-
ribosylated targets.217 ADP-ribose can be linked to either
negatively charged glutamates and aspartates via ester bonds
that are highly sensitive to hydroxylamine or to positively
charged arginine or lysine residues via N-glycosidic bonds that
are resistant to hydroxylamine treatment as well as to cysteine
and asparagine residues.218 Interestingly, most known mARTs
transfer ADP-ribose onto arginine or lysine residues, whereas
pARTs mainly target glutamate residues.219 Notably, ARTs are
mainly extracellular enzymes that modify integrins and growth
factor receptors. The only known intracellular enzymes
possessing mono-ADP-ribosyltransferase activity are members
of the sirtuin (SIRT) family of NAD+-dependent deacetylases.
Sirtuins SIRT1, SIRT2, SIRT4, and SIRT6 harbor weak
intrinsic mono-ADP-ribosylation activity, transferring a single
ADP-ribose to an arginine residue of speciﬁc target
proteins.220,221 There are three ARH and one poly-ADP-ribose
glycohydrolase (PARG) known in humans. The poly-ADP-
ribose polymer can be degraded by PARG and ARH3, which
hydrolyze glycosidic bonds between two ADP-ribose units, thus
removing ADP-ribose moieties from the polymers. The only
enzyme able to release a mono-ADP-ribose moiety from ADP-
ribosylated proteins is ARH1, which cleaves oﬀ a mono-ADP-
ribose from arginine residues.222
Figure 49. Generation of ADP-ribosylated arginines is catalyzed by ART enzymes, while the hydrolysis of peptidyl ADP-ribosylated arginine residues
is mediated by ARH enzymes.
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Several decades ago, it was shown that histone proteins can
be ADP-ribosylated.223 There, it was reported that ADP-
ribosylated histone proteins contain primarily ADP-ribose
monomers or short oligomers rather than long polymers.223b
Despite some evidence that histone proteins can be ADP-
ribosylated on arginine residues, further studies are necessary to
unequivocally prove the presence of ADP-ribosylated histones
and to identify the underlying transferase enzyme(s).
4.3. Histone Arginylation
Histone proteins are also subject to protein arginylation, which
represents the post-translational addition of an arginine residue.
This type of modiﬁcation aﬀects the proteolytically processed
and thereby exposed α-amine of histone H2B type 2-B at Q48
and A59, histone H4 at T136 and V116, and histone H2A.1 at
S41, as well as histone H1 at L61.224 Interestingly, arginylation
sites can be further modiﬁed by arginine methylation. On the
basis of structural modeling, arginylation of histone proteins
potentially facilitates the interaction of the histones with DNA
due to the introduced positive charge of the additional arginine
residue.224b Protein arginylation is mediated by the arginyl-
tRNA-protein transferase 1 (ATE1), which transfers a single
tRNA-bound arginine onto proteins (Figure 50).225 Typically,
arginylation occurs at the unprotected N-terminal α-amino
groups. However, following proteolytic processing, internal α-
amino groups can be arginylated in vivo.224a It was proposed
that the main function of protein arginylation is to mark target
protein substrates for degradation by the ubiquitin-dependent
N-end rule pathway.226 However, the detailed functions and the
extent of histone arginylation are currently not known.
5. CONCLUDING REMARKS
Epigenetic regulation governed by arginine modiﬁcation is an
emerging hallmark of eukaryotic organisms, and interference
with the underlying enzymes holds great promise to intervene
in various diseases ranging from cancer to rheumatoid arthritis.
The abundance of various histone modiﬁcations on nucleo-
somes implies that crosstalk between these modiﬁcations is very
likely. Diﬀerent types of modiﬁcations occur on arginine
residues, resulting in some form of antagonism since distinct
types of modiﬁcations on arginines are mutually exclusive. In
addition, the introduction of arginine modiﬁcations can either
create or compromise a substrate recognition site for other
histone-modifying enzymes even spanning diﬀerent histone
tails. The molecular details of such communication between
modiﬁcations are a topic of intense research. In this respect, it is
interesting to note that PAD-mediated histone citrullination
functions as a general opponent of methylation by PRMTs.
Depending on the methylation signal, i.e., activating or
inhibiting, PADs might act as a repressor if activating arginine
methylation is inhibited or an activator if the balance of PAD
activity is shifted toward the suppression of a repressive
arginine methylation mark.
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ABBREVIATIONS
ABPP activity-based protein proﬁling
ADP adenosine diphosphate
AMP adenosine monophosphate
ARH ADP-ribosyl hydrolase
ART ADP-ribosyltransferase
ATE arginyl-tRNA-protein transferase
ATP adenosine triphosphate
ADMA asymmetric dimethylarginine
BAA benzoyl-L-arginine amide
bp base pair
Bz-ADMA benzoyl-Nω,Nω-dimethylarginine
CID collision-induced dissociation
ChIP chromatin immunoprecipitation
DFT density functional theory
DTT dithiothreitol
ER estrogen receptor
ES cells embryonic stem cells
ETD electron-transferring dissociation
FAD ﬂavin adenine dinucleotide
Fluopol-ABPP ﬂuorescence polarization activity-based protein
proﬁling
HTS high-throughput screening
LSD lysine-speciﬁc demethylases
MMA monomethylarginine
MS multiple sclerosis
NAD nicotinamide adenine dinucleotide
NET neutrophil extracellular trap
NLS nuclear localization signal
PAD protein arginine deiminase
PAP protein arginine phosphatase
PAK protein arginine kinase
PCMB p-chloromercuribenzoate
PRMT protein arginine methyltransferase
PTM post-translational modiﬁcation
PTP protein tyrosine phosphatase
QM quantum mechanical
RA rheumatoid arthritis
SAH S-adenosyl-L-homocysteine
SAM S-adenosyl-L-methionine
SAXS small-angle X-ray scattering
SDMA symmetric dimethylarginine
SN2 reaction bimolecular nucleophilic substitution reaction
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